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Abstract 
My graduate research has used engineered peptides to perturb the non-covalent interactions in 
protein folding, protein-protein association and protein-membrane association. We have focused 
on understanding the fundamental principles of molecular recognition behind protein-protein and 
protein-membrane interactions, and further using these principles in protein engineering. This 
thesis includes three projects. 
I) Towards Small Molecule Receptors for Membrane Lipids: A Case Study on 
Phosphatidylserine 
The lipid composition and distribution of cell membranes play important roles in regulating 
the physiology of the cell. The lipid composition of plasma membranes is one characteristic 
feature that can be used to identify cell types and functions. Molecules that specifically recognize 
a particular lipid are useful as imaging probes for targeting cells or tissues of interest. Protein 
based lipid binding probes have intrinsic limitations due to their large size and poor 
pharmacokinetic properties such as slow clearance rate and poor in vivo stability. A plausible 
strategy to achieve a probe with small size and high binding affinity and selectivity is to use a 
peptide to mimic the protein lipid-binding domains. As a case study, a cyclic peptide that 
specifically targets phosphatidylserine containing membranes has been developed. This cyclic 
peptide is potentially capable of imaging apoptosis in vivo, and the strategy of developing this 
cyclic peptide can be generalized to the design of peptide-based probes for other lipid species. My 
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research has pointed out a challenging but feasible way to design a peptide that achieves 
specificity and affinity similar to lipid-binding proteins. 
 
(II) Study of Apoptotic Cell Membrane (ACM) Permeant Molecules 
Noninvasive imaging of apoptosis is highly desirable for the diagnosis of a variety of 
diseases, as well as for the early prognosis of anticancer treatments. One characteristic feature of 
apoptotic cells that has been targeted for developing specific biomarkers is enhanced membrane 
permeability compared to that of healthy cells. Several unrelated molecules that are capable of 
selectively penetrating the apoptotic cell membrane (ACM) have recently been reported. 
However, the origin of the altered ACM permeability is poorly understood, as is the scope of 
molecular structures that can permeate through the ACM. Herein, we report a systematic 
investigation on the altered ACM permeability. Our results show that simple modifications of 
commonly used dyes (e.g. fluorescein) afford specific entry into cells at the early stages of 
apoptosis. The ACM appears to be permeable to molecules of various functional groups and 
charge, but does discriminate against molecules of large size. The new findings reported here 
greatly expand the pool of small molecules for imaging cell death, thus facilitating the 
development of noninvasive imaging agents for apoptosis. 
 
(III) Study of Aromatic-Fluorinated Aromatic Interactions in Peptide Systems 
Therapeutic proteins have been through a remarkable expansion in the last two decades. A 
general problem that they are facing is poor stability. Protein engineering focuses on solving this 
problem by incorporating unnatural amino acids into protein sequences to purposefully modify 
protein structures. Fluorinated aliphatic amino acids have been demonstrated to be effective in 
stabilizing protein structures and functioning as recognition motifs. In contrast, fluorinated 
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aromatic amino acids are less studied. We investigated the effect of perturbation of fluorination 
on aromatic residues on the stability of protein model systems, as well as the influence on 
protein-protein association behavior. The results of this study provided a fundamental 
understanding of aromatic interactions in protein systems, and guidelines for protein engineering 
with fluorinated aromatics for stabilizing protein structures or directing specific protein-protein 
interactions. 
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Chapter 1. Towards Small Molecule Receptors for Membrane Lipids: A Case Study on 
Phosphatidylserine 
 
1.1 Introduction 
 As one class of compounds essential to biology, lipids can be used as energy storage, in 
signal transduction, and most importantly as structural building blocks. The lipid membrane  
functions as a barrier that allows cell to segregate their internal components from the outside 
environment and provides a confined space for biochemical events to take place with high 
efficiency.
1
 Membrane lipids can also serve as receptors for signaling across the lipid bilayer.
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For example, it is well known that glycolipids can serve as membrane receptors that define the 
blood type.
3
 However, it is increasingly clear that many other lipid species, such as 
phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), 
sphingolipids, and cholesterol, also have been utilized for protein recognition. Recruiting proteins 
that recognize different lipids is essential for intracellular functions and intercellular 
communications, chemical exchange and maintenance  of the cell structure.
4
  
Tracking a specific lipid species on the cell plasma membrane can help us to understand the 
biological events related to the lipid distribution and dynamics on the cell surface. For example, 
phagocytosis and blood coagulation are mediated by PS,
5
 cell division is related to PE
6
 and 
intercellular communication is related to lipid rafts enriched with cholesterol and sphingolipids
7
. 
Furthermore, the ongoing research in the field of lipidomics provides growing knowledge about 
the lipid profile for different types of cell membranes.
8
 Therefore molecules that specifically 
recognize a particular lipid composition are useful as imaging probes for targeting cells or tissues 
of interest. 
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Currently, most of the commonly used probes for imaging membrane lipid composition have 
been developed from lipid binding proteins.
9
 However, proteins have intrinsic limitations due to 
their large size and poor pharmacokinetics such as slow clearance rate and poor in vivo stability. 
These limitations can be circumvented by using small molecules that display protein-like 
specificity for lipids. The high binding affinity and specificity of proteins can be attributed to the 
well evolved structures that enable proteins to engage in multiple noncovalent interactions with 
the ligand simultaneously in a confined space which is often referred to as a “binding pocket”. 
However, small molecules are much simpler and normally involved in fewer interactions with the 
ligand, therefore affording poorer affinity and selectivity than proteins. Peptides are smaller than 
proteins in size and are more easily synthesized and modified. A plausible strategy to achieve 
both small size and high binding affinity and selectivity is to use peptide backbone conformation 
and side chain functional groups to mimick the protein lipid-binding domains. There are a limited 
number of examples of lipid-targeting peptides in nature from which we can draw lessons from.
10, 
11
 Besides referring to the previous examples, investigations of protein lipid-binding domains can 
help us learn their structural features, leading to the development of peptide probes that can 
mimic the structure and function of lipid-binding domains.   
Here I will introduce some recent progress in this area, focusing on the design perspective in 
developing small molecules, in particular peptide-based probes for targeting different lipid 
species. As a case study, I will introduce my research on developing a cyclic peptide that 
specifically targets phosphatidylserine. This cyclic peptide is potentially capable of imaging 
apoptosis in vivo, and the strategy of developing this cyclic peptide can be generalized to the 
design of peptide-based probes for other lipid species. My research has pointed out a challenging 
but feasible way to design a peptide that achieves similar specificity and affinity as lipid binding 
proteins. 
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1.1.1 Lessons from antimicrobial peptides  
Phosphatidylglycerol (PG) and phosphatidylethanolamine (PE) are two major components of 
the bacterial plasma membrane. For example, in the outer membrane of the Gram-negative 
bacteria pseudomonas BAL-31, 16 % of the phospholipid species is PG, 78.9% is PE and the rest 
are other lipids.
12
 Nature has developed a number of antimicrobial peptides that are capable of 
specifically targeting bacterial membranes.
13
 The lipid-recognization mechanisms of natural 
antimicrobial peptides can be used as guidelines for engineering peptide probes to target other 
lipid species. 
 
1.1.1.1 Peptides target phosphatidylglycerol containing membrane 
 
Figure 1-1. Structures of common phospholipid headgroups and cholesterol 
PG is negatively charged. Therefore bacterial membranes containing PG are highly 
negatively charged (Figure 1-1). In contrast, the plasma membrane of mammalian cells generally 
contains neutral lipids such as PC, PE, cholesterol and sphingolipids on the outer leaflet and 
localizes negatively charged lipids such as PS on the inner leaflet. Therefore, targeting the 
negative charge is a straightforward strategy for targeting PG-containing membranes. In fact, 
most antimicrobial peptides are cationic and target the bacterial lipid membrane through 
favorable charge-charge attractions.  
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A common structure feature for most cationic 
antimicrobial peptides (CAMPs) is an amphiphilic 
secondary structure,
14
 with magainin II as a typical 
example (Figure 1-2). The net positive charge of a 
CAMP allows it to differentiate the negatively 
charged bacterial membrane from the neutral charged 
mammalian cell membrane. The amphiphilic structure 
allows the peptide to form a pore or simply dissolve 
the membrane in a detergent like mechanism (carpet 
model),
14
 thus causing cell membranes to leak and 
eventually kill bacteria. The membrane binding step is the key step that determines the specificity 
of CAMPs to bacterial membrane. The membrane insertion and disruption steps are correlated to 
the membrane-lytic activity but not the selectivity of CAMPs. Since we are focusing on the lipid 
recognition property of CAMPs, it is not our intention to discuss the structural features related to 
the activity of CAMPs here. 
The all-D-enantiomers exhibit the same selectivity as the native CAMPs. This demonstrated a 
non-receptor type interaction between the peptide and the bacterial membrane.
15
 In fact, for most 
of the membrane bound CAMPs, the hydrophobic surface is buried into the membrane and the 
hydrophilic surface is exposed to the solvent.
16
 Since the charged residues are located on the 
hydrophilic surfaces, the columbic interaction between the net charges of a CAMP and the 
membrane could be easily influenced by the solvent ion strength. In fact, many in vitro assays for 
the antimicrobial activity of CAMPs were tested under low ionic strength conditions and without 
any interfering substances that exist in vivo. In a higher ion concentration, CAMPs may lose 
selectivity and exhibit toxicity towards mammalian cells.
17
   
Figure 1-2. Amphiphilc structure of 
CAMP magainin II. The hydrophobic side 
of the α-helix comprises Ile, Phe and Leu. 
The hydrophilic side comprises polar and 
positively charged side chains such as Lys 
and His. 
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Besides overall charge, peptide conformation also plays a major role in lipid binding. It has 
been observed that many α-helical CAMPs are not well structured in the solution phase, 
exhibiting extended or random coil conformations. Upon binding to the lipid membrane, the 
peptide is allowed to adopt a highly structured α-helical conformation.18 The extent of the α-
helical conformation for a CAMP correlates to the negative charge density on the membrane.
19, 20
 
It suggests that the interactions between the peptide and the charged lipid headgroups might 
promote the peptide folding on the membrane. This is actually beneficial for α-helical CAMPs to 
avoid nonspecifical membrane-lytic activity to host cell membranes. This conformational 
transition provides an additional recognition mechanism other than purely charge-charge 
interactions, but it is not necessary for all CAMPs. For example, the conformation of membrane 
bound tachyplesin, a cyclic β-sheet peptide, remains the same as in the aqueous phase, largely 
because  a disulfide bond constrains the peptide backbone.
21
   
In fact, for some CAMPs with less ordered conformations, it has been observed that a less 
flexible structure would enhance both the binding affinity and selectivity. For example, a cyclic 
tryptophan rich antimicrobial peptide (cyclo-RRWWRF) showed a more than ten-fold increase in 
antimicrobial activity compared to the linear version, but only a three-fold increase in hemolytic 
activity.
22, 23
 It also showed a selective binding to the DPPG (1,2-dipalmitoyl-sn-glycero-3-
phospho-(1'-rac-glycerol)) headgroup over not only neutral lipids such as DMPC (1,2-
dimyristoyl-sn-glycero-3-phosphocholine), DPPE (1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine), but also other negatively charged lipids, including DMPA (1,2-
dimyristoyl-sn-glycero-3-phosphate), DPPS (1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine) and 
cardiolipin. The linear peptide displayed a random coil structure in buffer and a more ordered 
conformation in SDS micelles, but the cyclic peptide showed little conformational difference with 
or without SDS. Although it is difficult to interpret the CD spectra due to the aromatic clusters on 
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the small cyclic peptide, it suggests the conformational constraint of the cyclic peptide could 
contribute to its selectivity by preorganizing its conformation in the aqueous phase.  
Similarly, a ten-fold enhancement in binding affinity to PG containing membranes has also 
been observed with the cyclized β-hairpin antimicrobial peptide BPC194 compared to its linear 
analogue,
24
 though both the linear and cyclic peptides are not well structured in solution. Upon 
binding, the cyclic peptide easily adopts the β-hairpin conformation, but the linear peptide is still 
unstructured. This suggests that cyclization enhances the lipid-peptide interaction through 
facilitating the conformational change of the peptide.  
From a molecular design perspective, cyclization restricts the number of possible peptide 
conformations, forcing it to form an ordered structure that favors the orientations of its charged 
side chains and hydrophobic side chains towards opposite direction. In other words, cyclized 
peptides afford fewer structure conformers and higher local charge density comparing to their 
linear analogues.  
 
1.1.1.2 Peptides targeting phosphatidylethanolamine-containing membranes 
Phosphatidylethanolamine (PE, Figure 1-1) is the most abundant lipid in the bacterial 
membrane, and the second most abundant in animal and plant cells.
25
 The relatively small 
headgroup of PE renders it a cone shape that induces negative curvature in the membrane. 
Therefore PE primarily locates in the inner leaflet of the lipid bilayer. It has been observed that 
externalized PE correlates to cytokinesis, apoptotic cell phagocytosis, and protein C 
anticoagulation mechanisms.
26-28
 Recent research indicates PE is also exposed in tumor vascular 
endothelium cells, which can serve as a target for tumor imaging or drug delivery.
29
 A commonly 
used PE detecting probe is a peptide called cinnamycin.
30
 Cinnamycin belongs to the type B 
lantibiotics family produced by streptomycetes and was identified about 20 years ago. It was 
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found to specifically bind to PE in a 1:1 stoichiometry. Since then, cinnamycin and its analogues 
have been widely used as molecular probes for targeting PE.
10
 
The binding of cinnamycin to PE is highly specific: the dissociation constant (Kd) of 
cinnamycin with PE is about 10 nM, in comparison to about 10 mM with PC.
31
  The high binding 
affinity and selectivity for PE is presumably attributed to the rigidified conformation of 
cinnamycin. The NMR structure of a 1:1 cinnamycin and lyso-PE complex in DMSO solution 
indicates that the peptide forms an amphiphilic cylinder with the polar residues on one end and 
hydrophobic residues on the other end.
32
 The backbone of cinnamycin is cross-linked with four 
covalent thioether bonds, forming a binding pocket that specifically fits around the PE headgroup. 
The binding pocket locates at the hydrophobic side of the cylinder and only one carboxylate 
group on β-hydroxyaspartate at “Asp*15” is responsible for the polar interaction with the PE 
headgroup amine. The small volume of the binding pocket fits the PE headgroup well and 
explains the high specificity, but the structure does not show any hydrophobic interactions 
between the hydrophobic residues and the fatty acyl chain of the lyso-PE molecule. 
 
Figure 1-3. A) Sequence of cinnamycin. D* represents β-hydroxyaspartate. B) NMR structure of the 
cinnamycin and lyso-PE complex. Lyso-PE headgroup inserts into the hydrophobic pocket of cinnamycin. 
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Yellow circle highlighted the only residue involved in major polar interaction that was found in the 
complex, the β-hydroxyaspartate.  
Experimental studies showed that, for cinnamycin binding to membrane associated PE, an 
optimized length of the lipid acyl chain is eight carbons.
31
 Shorter length resulted in weaker 
binding, and longer length did not improve binding. This observation suggests that a preferred 
depth for the insertion of the peptide’s hydrophobic side chains is about 8-10 carbons. This 
contradicts the NMR structure which suggests that the binding of PE does not involve the acyl 
chains. Since the NMR structure was obtained in DMSO with a 1:1 complex of cinnamycin and 
lyso-PE, it is possibly different from the membrane-bound state, where the peptide hydrophobic 
motif could potentially be buried into the lipid bilayer. By exploring the amphiphilic structure of 
cinnamycin, it is reasonable to speculate that the headgroup of PE might interact with the polar 
side chains located on the hydrophilic side of the cinnamycin structure and the fatty acyl chain 
could be buried in the groove on the hydrophobic side. This speculation explains the optimized 
depth of the membrane insertion, since the acyl chain of eight carbons matches the length of the 
hydrophobic groove. 
Although cinnamycin has been known for nearly two decades, we are still unable to rationally 
design a peptide that affords similar binding affinity and selectivity for targeting a lipid molecule. 
Comparing cinnamycin to the cyclic antimicrobial peptides reveals two similar structural features: 
First is the amphiphilic structure. Both types of peptides possess a hydrophobic cluster 
responsible for membrane insertion. The polar region of the cyclic antimicrobial peptide provides 
a net charge that establishes a columbic interaction with the membrane. The polar region of 
cinnamycin is speculated to provide polar interactions with one particular lipid headgroup to 
afford high specificity.  
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Second is the constrained conformation. Intuitively, this allows both cyclic antimicrobial 
peptides and cinnamycin to reduce the entropic penalty of conformational change upon binding. 
Especially for cinnamycin, the tetracyclic structure further improves the selectivity by restricting 
the size of the binding pocket, thus preventing binding with larger lipid headgroups. These two 
common structural features were utilized in my design strategy for a PS-targeting peptide, which 
will be discussed in the second section of this chapter. 
 
1.1.2 Molecules that target cholesterol 
Cholesterol is a major component of the mammalian cell membrane. It serves as a building 
block to maintain the membrane physical state, and together with sphingomyelin (SM), is 
responsible for lipid microdomains formation.
33
 The lipid microdomains, commonly known as 
lipid “rafts”, are believed to recruit cell-surface proteins essential for signal transduction across 
the membrane.
34, 35
 Cholesterol-binding molecules can potentially serve as probes for tracking the 
membrane location and dynamics of cholesterol, which are related to the biological functions of 
lipid rafts. Examples of cholesterol-recognizing molecules include polyenes, such as filipin,
36
 
cholesterol-dependent cytolysins (CDCs),
37, 38
 enzymes, such as cholesterol oxidases,
39
 and other 
proteins with cholesterol binding domains, such as cholesterol binding tunnels/cavities.
40
 
Compared to the loosely packed lipid bilayer, there will be less water penetration in the lipid 
microdomains formed by the densely packed cholesterol and SM.
41
 Therefore fluorescent 
molecules sensitive to the environment polarity have been developed to monitor the physical state 
of the lipid bilayer.  For example, the emission of the fluorescent dye laurdan (Figure 1-4) 
exhibits a 50-nm red shift when membranes undergo a phase transition from gel to fluid. It has 
been used to monitor the lipid phase separation on cell membranes.
42
 Other environment-sensitive 
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dyes such as di-4-ANEPPDHQ
43
, 3-hydroxyflavone derivatives
44
 (F2N12S in Figure 1-4) and 
Nile Red derivatives
45
 (NR12S in Figure 1-4), have also been developed for the same application.  
 
Figure 1-4. Environment-sensitive dyes used for visualizing cholesterol-enriched lipid domains.  
The environment-sensitive small molecules report on the phase-separating behavior of 
cholesterol microdomains, which is an indirect indicator of cholesterol distribution. A more direct 
way of tracking cholesterol would be using molecules that selectively bind to cholesterol. 
Cholesterol-dependent cytolysins are a group of proteins that specifically target cholesterol-
containing membranes.
46
 These proteins are secreted by bacteria and generally bind to 
mammalian cell membranes, which contain cholesterol, and oligomerize to form pores that cause 
cell membrane leakage. Non-toxic versions of these proteins have been developed to detect 
membrane cholesterol. For example, a CDC called perfringolysin O (PFO) is modified to block 
its oligomerization but retain its cholesterol-selective binding.
47
 The modified version of PFO 
selectively binds to cholesterol-containing liposomes
48
 and mammalian cell membranes
49
 (in 
comparison with the cell membrane on which cholesterol is depleted by β-cyclodextrin). PFO 
derivatives have been used as markers for visualizing lipid rafts on cell membranes.
50
 
Although cholesterol-binding proteins can directly detect cholesterol on the membrane, their 
relatively large size (above 30 kDa) might limit the accessibility of these proteins to the 
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cholesterol located near areas of high dense membrane proteins.
51
 A peptide-based probe that 
mimics cholesterol-binding proteins can solve this problem due to its smaller size. Several short 
sequences from cholesterol-binding proteins have been identified for cholesterol recognition. For 
instance, the sequence of cholesterol recognition/interaction amino acids consensus (CRAC), 
“ATVLNYYVWRDNS” (the underlined residues are postulated to directly interact with 
cholesterol), has been identified as a cholesterol-binding motif with high binding affinity.
52
 The 
common sequence (-L/V-(X)
1-5
-Y-(X)
1-5
-R/K) is found in many cholesterol related proteins such 
as cholesterol-dependent GPCR,
53
 nicotinic acetylcholine receptor (AChR)
54
 and  the HIV-1 gp41 
protein.
55
 The isolated sequence of CRAC could give low nanomolar binding affinity to 
cholesterol containing membranes.
56
 However, to the best of my knowledge, using a CRAC 
containing peptide as a cholesterol probe in live cell imaging have not been reported. 
 
1.1.3 Targeting phosphatidylserine containing membrane  
Phosphatidylserine (PS) is the most abundant 
negatively charged lipid species in mammalian cell 
membranes.
5
 It comprises about 2-10% of total cell 
lipids and exclusively locates in the inner leaflet 
(Figure 1-5).
9
 PS serves as a structural component of 
membranes, and also is thought to recruit intracellular 
proteins onto the inner leaflet of cell plasma 
membrane. For example, PS in the inner leaflet has 
been shown to interact with skeletal proteins, thus 
modulating the mechanical stability of the cell 
membrane.
57
 In addition, PS is involved in cell 
Figure 1-5. Lipid asymmetric distribution 
on plasma membrane. SM: sphingomyelin; 
PI: phosphatidylinositol; PIP: 
phosphatidylinositol phosphate; PIP2: 
phosphatidylinositol biphosphate ; PA, 
phosphatidic acid 
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signaling pathways such as the protein kinase C pathways. When PS is externalized, it functions 
as a mediator in many intercellular events, such as blood coagulations and phagocytosis. There 
are a few cell types presenting membrane-exposed PS, including aging erythrocytes, apoptotic 
cells and tumor blood vessel endothelial cells.
58-60
 Therefore, membrane-exposed PS can 
potentially serve as a target for imaging apoptosis and tumors. 
Among the limited number of PS-targeting ligands, 
annexin V has been most extensively investigated for 
detecting apoptotic cells in vitro and in living organisms. 
Annexin V is a 36kDa protein that specifically binds to 
PS rich membranes with nanomolar affinity (0.1~2 nM).
61
 
The binding of annexin V to the PS headgroup is Ca
2+
 
dependent.
62
 The protein backbone carbonyl and side 
chain carboxylate coordinate with the positive Ca
2+
, 
which recognizes the negatively charged PS headgroup 
(Figure 1-6).
63
 Unfortunately, this binding mechanism 
limits the application of annexin V: under the ideal 
concentration of Ca
2+
 for annexin V binding (around 2 mM), it is possible that the membrane 
lipid scramblases could be activated, which can transport phospholipid including PS 
bidirectionally across the lipid bilayer.
64
 This will result in a falsely positive signal of apoptosis 
detection. Furthermore, since the physiological extracellular Ca
2+ 
concentration is around 1.25 
mM and the binding affinity of annexin V to cells varies dramatically over a Ca
2+
 concentration 
range of 1.25~2.25 mM, this makes the annexin V staining of apoptosis difficult to quantify in 
vivo.
62
  
Figure 1-6. The binding pocket of 
annexin V for PS headgroup 
recognition through coordinating with 
Ca
2+
. The purple spheres represent 
Ca
2+
. PDB:1A8A 
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In general, proteins like annexin V are less than ideal for PS imaging due to their moderate 
stability and slow clearance in living organisms. For example, the optimal imaging time is 
between 10 and 15 hours after injection due to the slow clearance rate of annexin V in the blood 
stream.
65
 These protein-based probes, therefore, are unsuitable for situations where an immediate 
diagnosis is required. Small molecules that specifically target PS may circumvent the problems 
afflicting annexin V, and their development has captured increasing attention. 
 
1.1.3.1 Small molecule probes that target PS for apoptosis imaging 
Smith et al. have developed a group of small molecules 
that mimic annexin V for targeting PS-containing membranes. 
These molecules contains two Zn
2+
-DPA (dipicolylamine) 
subunits which serve as positive centers that are able to 
specifically target anionic lipid headgroups (Figure 1-7) with 
about 500 nM binding affinity.
66
 This molecule has been 
conjugated to different fluorophores and used for labeling 
apoptotic cells in vitro and in vivo.  
Although this probe works effectively in vivo as a 
qualitative apoptosis imaging probe,
67
 it faces similar problem 
as annexin V due to the cation dependent binding mechanism: since the Kd for the second Zn
2+
 to 
the DPA motif is about 10 µM, which is in the range of the physiological Zn
2+
 concentration, the 
quantitative imaging of apoptosis in vivo is a potential concern. 
 
 
 
Figure 1-7. The structure of the 
Zn
2+
-DPA complex in the PS 
binding molecules. The R 
represents a reporter group 
conjugated on the PS binding 
motif with a PEG linker. 
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1.1.3.2 Peptide-based probes that target PS for apoptosis imaging 
Only a few peptide-based probes that specifically target PS have been developed. For 
example, a cyclic peptide was identified by a phage displayed library containing random 
sequences as (CXXXXXXC).
68
 The phage library was undergoing four rounds of biopanning for 
selective binding to PS lipid covered surface over PC-covered surface. One predominant enriched 
peptide sequence after screening is CLSYYPSYC. The phage particles containing the peptide 
sequence showed over 20-fold more selectivity for PS-coated surface binding over PC. However, 
the selectivity and binding affinity of the peptide alone is not provided by the author.  
Short sequences from PS-binding domains have also been isolated and used as templates to 
screen for PS-targeting peptides. For instance, a peptide sequence FNFRLKAGQKIRFG (termed 
PSBP-0) was identified from the PS-binding site of PS decarboxylase which is an endogenous 
protein capable of binding PS.
69
 PSBP-0 showed modest binding affinity (apparent Kd is 5~50 
µM) and selectivity for PS over other lipids. An alanine scan showed that the Q to A mutation 
gives a modest increase of the binding affinity for PS of about 6-fold. However, the reason for the 
enhanced binding affinity of the mutant was not clearly addressed. Since the peptide is highly 
positively charged, the PS binding could simply rise from net charge-charge interaction between 
the peptide and membrane, which could be less specific in vivo when the ion strength is high. 
  
1.1.4 Summary for developing small molecule probes for lipid targeting 
As molecular probes, small molecules have an intrinsic advantage over proteins, since 
proteins are generally difficult to chemically label, and afford slow clearance rates and short half-
life in blood. Small molecules circumvent these drawbacks but their simpler structures generally 
afford lower binding affinity and selectivity.  
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Peptide probes have great potential because they are easy to synthesize, convenient for 
chemical labeling, and afford more favorable pharmacokinetic properties such as faster clearance 
rate and higher proteolytic stability compared to proteins. Peptides are also likely to possess 
higher selectivity by engaging in multiple interactions with the ligand, analogous to a large 
protein. However, the current strategy for developing peptide probes is mainly based on screening 
and the initial screening usually will not generate high potent leads due to the high 
conformational flexibility of the peptide. The conformational change upon binding costs a large 
entropic penalty. Alternatively, since a number of lipid-binding proteins have been discovered 
and the characterizations of their lipid-binding domain are ongoing, it is a potential direction to 
design peptides that mimic the lipid-binding domain. The knowledge gained from cinnamycin 
and cyclic antimicrobial peptide can serve as guidelines in the design of peptides with restricted 
scaffolds that mimic the binding pocket of PS-binding proteins. 
Here I will introduce my research on developing a cyclic peptide targeting PS. There are 
three reasons for choosing PS as a target: first, PS has a negatively charged headgroup which is 
unique among the lipid species in mammalian cell membranes; second, membrane-exposed PS is 
involved in many biological events including apoptosis and blood coagulation, so detection of 
cells exposing PS could be useful in clinical diagnoses; finally, there are several PS-targeting 
proteins that have been identified, and their structures and PS-binding domains have been 
extensively studied. The peptide was designed by mimicking the PS-binding domain of a protein 
called lactadherin. Our experimental results in a liposome model system showed that the peptide 
selectively binds to PS-containing membrane with low micromolar affinity. A preliminary 
structure-binding relationship study has been carried out and it suggests a strong sequence 
dependence of the binding of this peptide to PS containing membranes. The fluorophore labeled 
peptide has been used for apoptotic cell imaging in vitro and showed the ability to differentiate 
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healthy cells from apoptotic cells across several cell lines. This peptide could potentially be used 
as a non-invasive apoptosis imaging probe in the clinic.  
A serendipitous discovery from this research is the discovery of a group of small molecules 
that are selectively permeant to apoptotic cell membranes. This selective apoptotic cell membrane 
permeability has been reported before, but the mechanism is still unclear, as well as the common 
structural features of the molecules permeant to apoptotic cell membranes. I have synthesized and 
tested a series of derivatives with different functional groups and expected this study will expand 
the scope of small molecules for apoptosis imaging. I will discuss this study in chapter II. 
 
1.2 Design of cyclic peptide targeting PS by mimicking a PS binding domain 
Membrane exposed PS functions as a mediator in many intercellular events, such as blood 
coagulations and phagocytosis. On the surface of apoptotic cells, PS functions as an “Eat-me” 
signal targeted by macrophages through mediating proteins such as lactadherin
70
 or directly 
through receptors on macrophages’ membrane such as stabilin-1.71 Therefore, PS exposure on the 
outer leaflet of the plasma membrane is a universal indicator of early-stage apoptotic cells, 
regardless of the cell type and apoptosis inducing condition. Targeting PS is a viable strategy for 
imaging apoptosis.  
Apoptosis is an essential process in all multi-cellular systems. It helps to regulate the 
homeostasis of cell populations. Disordered apoptosis regulation can lead to a variety of 
diseases.
72
 For instance, impaired apoptotic activity causes abnormal cell survival and is 
associated with tumor growth, cancer, autoimmune diseases, and inflammatory diseases. 
Conversely, undesired high levels of apoptosis results in initiation of cell death pathways on 
normal functioning tissue, as observed in neurodegenerative diseases (e.g., Parkinson’s disease, 
Alzheimer’s disease, dementia, and cerebral ischemia, among others) and infections. Therefore, 
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noninvasive imaging of apoptosis is potentially useful for assisting in the early detection of 
diseases, monitoring disease course and accessing the effect of chemotherapies for cancer 
treatment that function through activating cancer cell apoptosis.  
Besides annexin V, synaptotagmin and lactadherin are two proteins that selectively bind to 
PS containing membranes with nanomolar affinity and have been developed as apoptosis probes 
in vitro or/and in vivo. (Figure 1-8)
9
 
 
Figure 1-8. X-ray structures of the PS binding domains of annexin V (1AVR), synaptotagmin I (1BYN) 
and lactadherin (3BN6). The purple spheres represent Ca
2+
 and the blue layer represents PS containing 
membrane.
9
 
Synaptotagmin, a 65 kDa protein, recognizes negatively charged lipid membrane such as PS 
or PI containing membranes, through its C2A domain with a binding affinity of around 15~40 
nM.
73
. Similar to annexin V, the membrane binding of synaptotagmin-C2A domain requires Ca
2+
. 
Therefore synaptotagmin-C2A faces the same problem as annexin does: the difficulty of 
quantitative analysis due to its Ca
2+
 dependent binding mechanism. 
Lactadherin is a milk fat globule protein that serves as a bridge molecule, helping a 
macrophage to target apoptotic cells. There are four domains in lactadherin. The second EGF 
domain with a RGD containing region binds onto the integrin on macrophage membrane, and the 
C2 domain selectively binds to PS-displaying apoptotic cell membrane through a Ca
2+
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independent manner (Figure 1-9).
70, 74
 
Lactadherin C2 domain (lact-C2) has 
been studied in vitro for its selective 
binding to PS containing membranes, and 
has been proven to steroselectively bind 
to the PS headgroup with low nanomolar 
affinity and in a cation free manner.
75
 
Fluorophore labeled lact-C2 showed 
selective staining of early stage apoptotic 
cells.
76
 To date, no in vivo experiment using lactadherin as an apoptosis imaging probe has been 
reported. 
The binding of lact-C2 to PS containing membranes is stereoselective and does not require 
cation assistance, suggesting a receptor like mechanism. Though there is no structure data of the 
lipid-protein complex, the crystal structure of lact-C2 has been revealed.
77
 It is therefore 
reasonable to predict the protein lipid-binding domain through a computational docking 
experiment. Lact-C2 should be a good model for designing a peptide that mimics the structure of 
the potential binding pocket. 
 
1.2.1 Structure analysis of lact-C2 PS binding domain. 
 The lact-C2 structure displays a beta-barrel core and three loops projecting out for 
membrane insertion (Figure 1-10). While the structure of the Lact-C2-PS complex remains 
elusive, the mutagenesis data as well as computational modeling suggest two potential binding 
sites at the loop region (Surfaces C and D, as named by Shao et al.)
77
 for the PS headgroup. We 
focused on Surface D because computational docking experiments gave a more favorable binding 
Figure 1-9. Cartoon illustration of lactadherin 
mediating the recognition of an apoptotic cell by 
macrophage through PS binding. 
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free energy for the PS headgroup than PC: for 
the diacetyl-PS binding to Surface D, ΔG = -
14.74 kcal/mol; for the diacetyl PC binding to 
Surface D, ΔG=-7.78 kcal/mol. These data 
suggest Surface D selectively recognizes PS. 
(Collaborated with Dr. Qin Wang, see 
Experimental Procedures). Further structure 
examination revealed a number of residues 
critical for PS recognition (Figure 1-11): 
Phe81 and Trp26 belong to the group of 
hydrophobic residues that insert into the 
membrane, while the hydrophilic residues 
(Asp80, His83, Gln95, and Arg148) engage in 
specific polar interactions with the PS-
headgroup that afford the lipid selectivity. It is worth noting that most of the key residues, except 
for Trp 26 and Arg 148, are located on a single loop (loop3). This is encouraging for our peptide 
design because the conformation of the loop normally would be less structured compared to other 
parts of the protein, which suggests a high tolerance to the conformation of the designed peptide. 
The PS binding pocket looks like a bowl with the key residues displayed on the rim. Based on 
this observation, we hypothesized that the circular arrangement of these key residues can be 
recreated by the scaffold of a cyclic peptide. 
  
Ile
Potential site 
for labeling
Loops for membrane insertion
Figure 1-10. Crystal structure of Lact-C2 
(PDB: 3BN6), highlighting the membrane-
inserting loops and the key residues (in yellow) 
for PS recognition. The Ile residue projects 
away from the protein-PS interface, serving as 
an ideal site for fluorophore labeling.   
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Figure 1-11. The crystal structure of (A) lact-C2, (B) the potential binding pocket on surface D and the key 
residues for PS headgroup recognition, and (C) the docking model of Lact-C2 binding a short chain 
(diacetyl) PS. The model is based on lact-C2 crystal structure, PDB: 3BN6. 
 
1.2.2 Design, synthesis and in vitro binding test of cyclic peptide recognizing PS 
Our first design (cLac-1, Figure 1-12) 
positions a Trp and a Phe next to each other to 
generate a membrane insertion motif. Three of 
the four polar residues (Asp80, His83, and 
Gln85) involved in PS binding are in close 
proximity as in the primary sequence of lact-
C2. One notable exception is Arg148, which 
projects back into the vicinity of the other key 
Figure 1-12. Structural illustration of clac-1. The polar residues potentially engaged in polar interactions 
with PS headgroup are labeled in red; the hydrophobic side chains responsible for membrane insertion are 
labeled in blue; the original loop 3 backbone is black; the two glycine spacers are green. 
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residues in the folded protein. For the design of cLac-1, we linked Arg148 to the rest of the 
molecule by using two spacers: a dipeptide (-Gly-Gly-, Linker I) bridges Gln85 and Arg148, and 
a tripeptide (-Gly-Gly-Gly-, Linker II) links Arg148 and Trp26. In the native Lact-C2 domain the 
distance between Arg 148 and Gln 85 is 5.13 Å and the distance between Arg 148 and Asp 80 is 
9.60 Å. Molecular modeling of cLac-1 shows that the two linkers will be sufficiently long and 
flexible to allow recognition.  
 
Scheme 1-1. Synthetic route of the cyclic peptide cLac-2 through HBTU activation in the cyclization step. 
This cyclic peptide was firstly synthesized by using Fmoc/tBu chemistry (Scheme 1-1, also 
see Experimental Procedures). Asp, whose main chain was protected with allyl, was attached to 
Wang resin through its side chain carboxyl group. Standard solid phase peptide synthesis afforded 
the linear precursor with an unprotected N-terminus. Cyclization was accomplished on resin with 
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HBTU-mediated amide bond formation after removal of the allyl protecting group on Asp. 
However, this synthetic route has drawbacks, including low yield and dimerization caused 
primarily by the last HBTU activated cyclization step. In addition, to install a reporter group such 
onto the peptide, it is necessary for the peptide to have a bioorthogonal handle. Towards these 
ends, we have also developed an alternative way of making the cyclic peptides using native 
chemical ligation (Scheme 1-2, see Experimental Procedures for details). 
 
Scheme 1-2. Synthetic route of the cyclic peptide cLac-2 through native chemical ligation for cyclization. 
Peptide-membrane binding was evaluated by using a fluorescence assay: large unilamellar 
vesicles (∼100 nm in diameter) were prepared with 1-palmitoyl-2- oleoyl-sn-glycero-3-
phosphocholine (POPC) and varied percentages of 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-
serine (POPS). All vesicles contained 5% dansyl-labeled 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine (POPE) to serve as a reporter group. The peptide-vesicle binding was 
monitored by the fluorescence resonance energy transfer (FRET) from Trp to the dansyl group 
(Figure 1-13). Our 1
st
 generation of the designed peptide cLac-1, displays no binding to lipid 
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vesicles regardless of lipid composition (Figure 1-14). Presumably, the peptide is too hydrophilic 
to partition into the membranes. This is perhaps not surprising given that additional hydrophobic 
residues (Leu28 and Phe31) are necessary for Lact-C2 to insert into membranes.
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Figure 1-13. Cartoon illustration of the liposome based FRET assay to test the binding affinity and 
selectivity of cLac peptide to PS containing membrane. 
A more hydrophobic variant of cLac 
(cLac-2, Figure 1-15 A) was synthesized, 
which incorporates a biphenylalanine (Bip) in 
place of the Phe residue. The side chain of 
Bip has a cLogP value of 4.5, significantly 
greater than that of Phe (cLogP of 2.6). The 
FRET experiment shows no binding of cLac-
2 to the PC-alone liposomes. However, 
mixing cLac-2 with the PC/PS vesicles 
clearly elicits a sensitized dansyl emission at 
520 nm (Figure 1-15 B). Furthermore, the 
Figure 1-14. Membrane binding of cLac-1. Mixing of 
cLac-1 (5 M) and liposomes (with 0% and 20% PS 
respectively) elicits no increase of dansyl emission, 
indicating lack of binding of cLac-1 to either type of 
membranes. 
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sensitized dansyl emission becomes stronger with increasing concentrations of cLac-2. The 
titration results display a saturation profile, yielding an apparent dissociation constant (Kd) of ∼8 
μM. With cLac-2 at the saturating concentration (25 μM), the sensitized dansyl emission displays 
a linear dependence on the amount of PS presented by the membranes: vesicles containing 20% 
PS give close to 4-fold as much dansyl fluorescence as that of 5% PS (Figure 1-15 C). It is worth 
noting that cLac-2 displays no net charge under experimental conditions, suggesting its selective 
association with PS-presenting membranes is not merely driven by the electrostatic attraction to 
the negatively charged surfaces. This compares favorably to the cationic peptide-based ligands
68
 
and the organozinc complexes,
66
 which target PS predominantly through columbic interactions. 
 
Figure 1-15. (a) Structure of cLac-2, which 
incorporates biphenylalanine (Bip) as a 
membrane anchor; (b) cLac-2 (at 25 μM) 
sensitizes dansyl emission (highlighted by the 
arrows) only with PC/PS (20%) liposomes; (c) 
concentration profiles of cLac-2 binding to 
membranes with varied composition. 
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Further study of the structure-activity relationship shows that the linear precursor of cLac-2 
(Lac-linear) binds to neither type of vesicle (Figure 1-16 A), indicating that the circular 
arrangement of the key residues is necessary for the PS-dependent membrane association of the 
peptide. Our initial optimization of cLac-2 focused on the oligoglycine linkers. The number of 
Gly residues within Linker II was varied from 2 to 5. The Trp-to-dansyl FRET results (Figure 1-
16 B) show that cLac-22G (diglycine as linker II) elicits minimal dansyl emission, presumably 
because the linker is too short to allow the proper ring geometry for PS binding. Lengthening the 
linker to the tri- and tetraglycine moieties results in cLac-2 and cLac-24G respectively, which 
display a continued increase in dansyl emission, indicating an improved affinity of cLac for the 
membrane. Further expansion to the pentaglycine linker affords cLac-25G that gave a reduced 
dansyl emission, presumably because the excessive flexibility of the linker causes an 
overwhelming entropic penalty toward membrane binding. These data indicate that cLac-PS 
binding requires the cooperative action of multiple residues of the cLac peptide, analogous to the 
lipid binding mode of lactadherin, the protein that nature evolved for PS recognition. Interestingly, 
the peptide variants with varied lengths of Linker I (cLac-13G, cLac- 2, and cLac-33G, represent 
one, two and three glycines as linker I respectively) exhibit a much less significant difference in 
the peptides’ binding to membranes, possibly because the variation of Linker I can be effectively 
attenuated by the flexible Linker II (triglycine) on the other side of Arg148. 
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Figure 1-16. A) Membrane binding of Lac-linear. Lac-linear mixing with liposomes containing 0%, 5% 
and 20% PS elicits no dansyl emission, indicating that the linear variant does not bind to the membranes; B) 
SAR (structure-activity relationship) study of cLac-2 comparing the peptide variants with different linker 
lengths; all peptides are used at 25 μM concentration. 
Since the two charged residues Arg and Asp are connected through linker II, the fact that the 
length of linker II affects the peptide-PS binding affinity suggests the importance of the distance 
between these two charge centers. By mutating the two charged residues to Ala, the peptide 
exhibits dramatically different behavior. The mutants are compared by their relative binding 
affinities to four different liposomes. Besides PC liposomes and PC with 5% PS liposomes, since 
the mammalian cells contain ~30% cholesterol, two liposome suspensions (with and without 5% 
PS) containing 30% cholesterol were made to better mimic the mammalian cell membrane. The 
relative binding affinity of each individual peptide is represented by the FRET signal from the 
mixture of 25 µM peptide and 100 µM liposomes (Figure 1-17). The R/A mutant completely lost 
its capability of membrane binding, presumably due to the loss of the polar interaction between 
the Arg side chain and the lipid headgroup; the D/A mutant showed significant enhancement of 
binding affinity to all the four membranes with different lipid compositions, but the selectivity 
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towards PS containing membrane is decreased, presumably due to the loss of the interaction 
between Asp and the positive charged -NH2 on the PS headgroup.  
 
Figure 1-17. The binding affinity of R/A and D/A mutants of cLac-2 to membranes with different lipid 
compositions. All liposomes contain 5% dansyl-PE.  
We were curious about how different types of the hydrophobic residues could affect the 
membrane binding and selectivity. Therefore, we made a series of mutants with different 
hydrophobic residues installed at the biphenylalanine position (Figure 1-18). All peptides show 
higher binding to PS containing membranes compared to the membrane without PS, although the 
degree of selectivity is different. It is worth noting that the overall binding affinity of a peptide 
does not always correlate to its overall hydrophobicity. For example, the bromo- and the iodo-
phenylalanine side chains (log P 3.35 and 3.88 respectively) are more hydrophobic than the 
trifluorophenylalanine (log P 3.0), but the two trifluorophenylalanine mutants display higher 
binding affinity to any liposome composition compared to the bromo- and iodo- phenylalanine 
mutants. The two naphthalene mutants also show higher binding affinity than the bromo- and 
iodo- phenylalanine mutants, even though these four side chains have similar log P values.  
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Figure 1-18. The binding test for cLac variants with different hydrophobic residues. A) The structure of the 
hydrophobic side chains on the mutants; B) the relative binding affinity of each peptide to four different 
types of liposomes, represented by the FRET signal for the mixture of 25 µM peptide and 100 µM 
liposomes. All liposomes contain 5% dansyl-PE. 
The data presented here suggest that the peptide with a single mutation of the hydrophobic 
residues can already render a change of selectivity to different lipid compositions. Therefore, it is 
possible that the selectivity of a lipid binding protein comes not only from the polar interactions 
between polar side chains and lipid headgroups, but also from its hydrophobic motif inserted in 
the lipid bilayer.  For example, the two naphthalene mutants, almost structurally identical to each 
other, show different selectivity towards PS containing membranes: the naphthalene-1 (Np-1) 
mutant displays lower binding affinity to PS-free membranes, but higher binding affinity to PS 
containing membranes than the naphthalene-2 (Np-2) mutant. Furthermore, the Bip peptide 
shows selective binding to cholestoral containing membranes regardless of whether the 
membrane contains PS or not, but the other mutants do not differentiate membranes with or 
without cholesterol. One possible explanation is that the hydrophobic motif controls the depth of 
membrane insertion. Different hydrophobic side chains prefer different depths of insertion due to 
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their distinct desolvation energies and steric packing with the fatty acyl chains. This phenomenon 
might results in different Trp-Dansyl FRET signal intensities even though the binding affinities 
are identical.  
 
1.2.3 Imaging apoptotic cells with cLac peptide. 
In order to evaluate the potential of cLac as an imaging agent for apoptotic cells, we 
functionalized cLac-2 with a fluorescein label through bioorthogonal click chemistry.
78
 A 
propargyl glycine (Pra) was introduced to replace the Ile residue within the cLac-2 sequence. 
Based on the Lact-C2 structure (Figure 1-10), the Ile side chain projects away from the protein-
PS interface. Therefore we expect the Ile-to-Pra mutation to introduce minimal perturbation to the 
peptide-membrane association. Indeed, when the Pra derivative (cLac-2-Pra) was measured 
against liposomes with and without PS, membrane selectivity essentially identical to the parent 
peptide (Figure 1-19) was observed. A fluorescein moiety was conjugated onto cLac-2-Pra to 
give cLac- 2-Fl via click chemistry (Scheme 1-3), in which a flexible PEG linker bridges the 
fluorophore and the cyclic peptide. This design separates the fluorophore and the peptide so the 
specific binding of cLac to the membrane is minimally perturbed. Another convenient method of 
labeling the peptide with fluorophore is using a Cys as a handle to react with a maleimide linked 
fluorophore. Through native chemical ligation, we can cyclize the peptide and introduce a Cys 
onto the peptide structure simultaneously. The binding affinity and selectivity of the Cys mutant 
was measured with the liposome assay, and it showed identical PS specificity as the parent 
peptide (Figure 1-19). An alexa fluor® 488 was conjugated on the peptide through a five-carbon 
linker and a maleimide group. Apoptotic cell staining with this fluorophore labeled peptide is still 
ongoing. 
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Figure 1-19. The normalized FRET results of cLac-2-Pra and cLac-Cys binding to liposomes with 0% and 
5% PS, compared with cLac-2. cLac-2-Pra and cLac-Cys preferentially associate with PS-presenting 
membranes, similar to the parent peptide cLac-2. The relative intensity 1.0 refers to the intensity obtained 
from 25 µM of each peptide in 100 µM 5% PS liposomes. 
 
Scheme 1-3. Fluorescent labeling of cLac-2 through click chemistry.  
A B C D
A B C D
cLac-2-Pra cLac-2-Fl
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Scheme 1-4. Fluorescent labeling of cLac-Cys through maleimide conjugation. 
The fluorescent cLac-2-Fl was tested for its potential to stain apoptotic cells. Cultured HeLa 
cells were treated with the potent apoptogen staurosporine (STS) to trigger apoptosis. The 
experimental conditions were optimized with the FITC-labeled annexin V and propidium iodine 
(PI, a membrane impermeable DNA intercalator). Treatment with 1 μM STS for 3 h gave a large 
population of early apoptotic cells, which stained with annexin V, but not PI (Figure 1-20). 
Under these conditions, cLac-2-Fl (the green channel) readily stained STS treated cells, while 
little fluorescence was observed for the untreated cells (Figure 1-22). The lack of staining for the 
untreated cells indicates that cLac-Fl does not gain entry into healthy cells by diffusion or by 
endocytosis, a common outcome expected for most peptide based agents. As a negative control, 
we tested the FITC-labeled Lac-linear, which gave little staining of the apoptotic cells under the 
same experimental conditions (Figure 1-21). Collectively these results suggests that cLac-2-Fl 
recognizes apoptotic cells through a specific mechanism. The merged microscopy image (channel 
D, Figure 1-22) exhibits minimal overlay between cLac staining and PI fluorescence, indicating 
cLac largely detects early apoptotic cells. A similar phenomenon was observed for annexin V 
(Figure 1-20). Since these early apoptotic cells hold their membrane integrity (negative for PI 
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staining), we believe cLac2-Fl stained the cells by binding to their outer surfaces, presumably to 
PS.  
 
Figure 1-20. Fluorescence microscopy images of annexin V and PI stained HeLa cells. A, phase contrast; 
B, FITC channel; C, PI channel; D, overlay of B and C. A large population of cells was in the early stage of 
apoptosis. 
 
Figure 1-21. Fluorescence microscopy images of Lac-linear-Fl and PI stained HeLa cells. A, phase contrast; 
B, FITC channel; C, PI channel; D, overlay of B and C. No staining of the HeLa cells by Lac-linear-Fl was 
observed. 
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Figure 1-22. Microscopy analysis of cLac-2-Fl in staining apoptotic cells. (A) Phase contrast; (B) FITC 
channel; (C) PI channel; (D) overlay of B and C. Little staining of the nonapoptotic cells was observed for 
cLac-2-Fl. 
To test the generality of the cLac peptide, we further examined its potential in imaging Jurkat 
cells with both microscopy and flow cytometry. Jurkat cells were treated with and without 
camptothecin (CPT) and then stained with cLac-2-Fl and the FITC labeled annexin V, 
respectively. Analogous to the HeLa cells, cLac-2-Fl readily differentiated the CPT treated versus 
untreated Jurkat cells (bottom panel, Figure 1-22). The cLac staining of Jurkat cells was 
quantitatively evaluated via flow cytometry analysis (Figure 1-23). Similar to annexin V, which 
stains ∼16% of the CPT-treated cells, cLac-2-Fl labels ∼18% of the cell population of the 
identical sample. Presumably cLac-2 and annexin stain the same subpopulation of the cells that is 
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at the early stages of apoptosis. Lower fluorescence intensity was observed for the apoptotic cells 
treated with cLac-2-Fl than annexin V. This is partly because annexin V carries multiple copies of 
fluorophores (two to three copies conjugated onto lysine side chains), while cLac-2 is labeled 
with a single dye. The relatively low PS-binding affinity of the cLac peptide may also contribute 
to the low fluorescence intensity observed for the apoptotic cell population.  
 
Figure 1-23. Flow cytometry results illustrating the effectiveness of the cLac peptide in labeling apoptotic 
cells. Jurkat cells treated with (A, C) and without (B, D) camptothecin were analyzed with cLac-2-Fl (A, B) 
and FITC labeled Annexin V (C, D) respectively. For each graph, the cell population is plotted against the 
fluorescence intensity (in log scale) of the cells. The percentage of cell population and the mean 
fluorescence intensity are labeled for each peak. 
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1.3 Conclusions 
 
 
Figure 1-24. Flow cytometry (A, B) and fluorescence microscopy (C, D) results of annexin V staining 
Jurkat cells with (A, C) and without (B, D) Ca
2+
.  
In summary, we have developed a new class of cyclic peptides that successfully mimic the 
function of the natural PS-binding protein lactadherin. These cyclic lactadherin mimics (cLacs) 
selectively associate with PS-presenting membranes with low micromolar affinity. Furthermore, 
we demonstrate with two different cancer cell lines that a fluorescently labeled cLac effectively 
detects cells at the early stages of apoptosis. Importantly, the cLac-PS recognition does not 
require any metal cofactors and compares favorably to annexin V, whose PS binding affinity is 
highly sensitive to calcium concentrations (see ref 29 and also Figure 1-24). While the PS-
binding affinity and the brightness of the fluorescent labels remain to be optimized, the cLac 
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design benefits from its small size, ease of labeling, and cofactor-free PS recognition, which is 
highly promising for imaging apoptosis in cell cultures as well as in living organisms. In addition, 
the biomimetic approach that we used in the design of cLac should be extendable to the 
development of small molecule receptors for other lipid molecules. Research toward these 
directions is currently underway. 
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Experimental Procedures 
I. General methods 
Fmoc-Asp(Wang resin)-OAll and HBTU were purchased from Novabiochem (San Diego, 
CA). 2-(2-(2-chloroethoxy)ethoxy)ethanol and potassium phthalimide were purchased from TCI 
America (Portland, OR). The phospholipids were purchased from Avanti Polar Lipids (Alabaster, 
Al). Fmoc-(4, 4’)-Biphenylalanine (Fmoc-Bip) and Fmoc-L-propargylglycine (Fmoc-Pra) were 
purchased from Chem-Impex Int’l Inc (Wood Dale, IL). All other Fmoc-protected amino acids 
were purchased from Advanced Chemtech (Louisville, KY) or Chem-Impex Int’l Inc (Wood Dale, 
IL). PBS buffer, DMEM/High glucose media, RPMI 1640 media, and Pen/Strep were purchased 
from Thermal Scientific (Amarillo, TX). Fatty acid-free bovine serum albumin (BSA) and 0.25% 
Trypsin-EDTA solution were obtained from Invitrogen (Carlsbad, CA). Staurosporine (STS) was 
ordered from Cell Signaling (Danvers, MA). Camptothecin (CPT) was from MP Biomedicals 
LLC(Solon, OH). FITC-labeled annexin V (AV-FITC) and propidium iodide (PI) were purchased 
as an apoptotic cell detection kit from BD Biosciences (Chicago, IL). VALAP was prepared in 
house by melting and mixing equal amounts of Vaseline, Lanolin and paraffin wax, which were 
purchased from a local CVS Pharmacy.  All other chemicals were purchased from Sigma Aldrich 
(St. Louis, MO). Peptide synthesis was carried out on a Tribute peptide synthesizer (Protein 
Technologies, Tucson, AZ). 
1
H-NMR and 
13
C-NMR data were collected on a VNMRS 500MHz 
NMR spectrometer (Varian NMR Inc.). MS data were generated by Boston College Mass-Spec 
facilities. Peptide concentration measurements were performed on a Lambda 25 UV-Vis 
spectrometer (PerkinElmer, Waltham, MA). 
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II. Computational docking to evaluate PS-lactadherin binding 
Docking of the short chain (diacetyl) lipids into Lact-C2 (PDB:3BN6) was performed using 
the Glide module in the SCHRODINGER package. The grids for the two potential lipid binding 
sites, Surface C and D of Lact-C2,
77
 were centered on the centroids of the selected residues 
constituting surface C and D respectively. The docking experiment was carried out using the 
standard-precision mode firstly and then extra-precision mode without any constraints applied. 
The atomic partial charges of the lipids were obtained directly from the docking force filed.  
The relative binding free energies were calculated using the MM-GBSA method
79
 with 
OPLS 2005 force field in the PRIME module of the SCHRODINGER package. For the diacetyl-
PS binding to Surface D, ΔG = -14.74 kcal/mol; for the diacetyl PC binding to Surface D, ΔG=-
7.78 kcal/mol. These data suggest Surface D selectively recognizes PS.  
 
 III. Peptide synthesis and characterization 
The cLac peptides were synthesized through Fmoc/tBu chemistry with the preloaded resin 
(Fmoc-Asp(Wang resin)-OAll, Novabiochem) as the solid support. The syntheses were carried 
out on 0.1 mmole scale. Five equivalents of the Fmoc-protected natural amino acids were used 
for the coupling reaction. The incorporation of the unnatural amino acids, Fmoc-Bip and Fmoc-
Pra, was accomplished by using two equivalents of the Fmoc-protected amino acids and an 
extended coupling time (1 hour). A mixture of 60 mg tetrakis(triphenylphosphine)-palladium 
(Pd(PPh3)4) and 0.3 mL phenylsilane in 2 mL dichloromethane was used to remove the C-
terminal allyl protecting group on the Asp. The cyclization step accomplished by using HBTU (1 
equivalent) to activate the C-terminal –COOH. The cyclization reaction was allowed to proceed 
with shaking for 1 hr. The peptides were cleaved off the resin and globally deprotected with 
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reagent K (80% TFA, 5% H2O, 2.5% EDT, 5% thioanisole and 7.5% phenol). The crude products 
were purified by RP-HPLC (Waters Prep LC, Jupiter C18 Column).  
An alternative route for synthesis of the cyclic peptide is through native chemical ligation. 
The peptide were synthesized through standard Fmoc/tBu chemistry on the Dawson Dbz AM 
resin. The sequence of loading started from the Gly next the Gln and ended with a Cys next to 
Arg. The Cys is Boc protected at N-terminus. Then the resin with the linear peptide on it was 
treated with p-nitrophenyl chloroformate and DIPEA. The peptide was cleaved off from the resin 
with reagent K, and the linear peptide with the N-acyl-benzimidazolinone (Nbz) was purified 
through prep-HPLC. The purified linear peptide-Nbz was dissolved in a ligation buffer (0.2 M 
phosphate buffer, 1.5 M guanidine hydrochloride, 0.02 M 4-mercaptophenylacetic acid, 0.02 M 
TCEP, pH 7.3). After overnight incubation, the cyclized peptide (cLac-Cys) was purified through 
prep-HPLC. 
All peptides were characterized with LC-MS to confirm their identities and purities (>95%). 
The peptide concentrations were calibrated by measuring UV absorption at 275 nm (εBip, 
275=11200 M
-1
cm
-1
, εTrp, 275=5379 M
-1
cm
-1
, εpeptide, 275= 16580 M
-1
cm
-1
).
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The peptide sequences are listed below: 
 
Peptides 
Calculated 
Molecular 
Weight 
Found in Mass 
spectrometry 
cLac-1 
HN-WFGHIQGGRGGGD-C=O 
 
1326 Da 
 
1326 Da 
cLac-2 
HN-WBipGHIQGGRGGGD-C=O 
 
1402 Da 
 
1402 Da 
cLac-13G 
HN-WFGHIQGRGGGD-C=O 
 
1345 Da 
 
1347 Da 
cLac-33G 
HN-WFGHIQGGGRGGGD-C=O 
 
1459 Da 
 
1461 Da 
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cLac-22G 
HN-WBipGHIQGGRGGD-C=O 
 
 
1345 Da 
 
 
1345 Da 
 
cLac-24G 
HN-WBipGHIQGGRGGGGD-C=O 
 
 
1459 Da 
 
 
1459 Da 
 
cLac-25G 
HN-WBipGHIQGGRGGGGGD-C=O 
 
 
1516 Da 
 
 
1516 Da 
 
cLac-2-Pra 
HN-WFGHPraQGGRGGGD-C=O 
 
 
1384 Da 
 
 
1384 Da 
 
Lac-linear 
AcNH-DWBipGHIQGGRGGG-CONH2 
1461 Da 1462 Da 
Lac-linear-Pra 
AcNH-DWBipGHPraQGGRGGG-CONH2 
1443 Da 1444 Da 
cLac-Cys 
HN-CRGGGDWBipGHIQG-C=O 
 
1448 Da 1448 Da 
 
 
IV.  Synthesis of cLac-2-Fl 
Fluorescein isothiocyanate (FITC) was conjugated onto the peptide through click chemistry 
via an azido-PEG linker. The synthetic scheme for Azido-PEG-FITC 9 is shown below. The 
synthesis of the early intermediates (2, 3, 4, 5) followed previously reported protocols. 
81, 82 
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Scheme 1-5. Synthetic route of Azido-PEG-FITC 9. 
 
(6) tert-butyl (2-(2-(2-bromoethoxy)ethoxy)ethyl)carbamate  
Compound 5 (2.00 g, 8.03 mmol) and CBr4 (3.47 g, 10.5 mmol) were dissolved in 15 mL of 
DCM. PPh3 (3.00 g, 11.4 mmol) was dissolved in 5 mL DCM and kept stirring in ice-water bath. 
The mixture of compound 5 and CBr4 was slowly added into the PPh3/DCM solution at 0 ˚C. The 
reaction was allowed to proceed for 3 hrs before 50 mL of 4:1 hexane and diethyl ether was 
added in. The precipitates were filtered off and the filtrate was concentrated. The crude material 
was purified with silica gel chromatography (4:1 hexane and ethyl acetate) to give the desired 
product as colorless oil (1.64 g, 66%). 
1
H-NMR: CDCl3, 500 MHz, δ=1.44 (s, 9H), 3.30~3.33 (dd, 
2H), 3.47~3.50 (t, 2H), 3.54~3.56 (t, 2H), 3.62~3.64 (m, 2H), 3.66~3.68 (m, 2H), 3.80~3.82 (t, 
2H), 5.17 (s, 1H). 
13
C-NMR: CDCl3, 125.6 MHz, δ=28.3, 30.2, 40.2, 70.1, 70.2, 70.3, 71.1, 78.9, 
155.9. HRMS calculated for C11H23Br1N1O4 [MH
+
] 312.0811, found 312.0815. 
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(7) 2-(2-(2-bromoethoxy)ethoxy)ethanamine  
To remove the Boc protecting group, Compound 6 (1.4 g, 4.5 mmol) was treated with the 
mixture of 10 mL TFA, 0.5 mL water and 0.5 mL triisopropylsilane for 1 hr. The volatiles were 
evaporated and the product was dried under vacuum to give colorless oil. The completion of the 
reaction was confirmed by NMR analysis. 
1
H-NMR: CDCl3, 500MHz, δ=3.27 (s, 2H), 3.48~3.50 
(t, 2H), 3.68~3.69 (d, 4H), 3.76~3.78 (t, 2H), 3.81~3.84 (t, 2H), 13.71(s, 2H). 
13
C-NMR: CDCl3, 
125.6 MHz, δ=30.6, 40.2, 66.4, 70.1, 70.2, 71.1. HRMS calculated for C6H15Br1N1O2
+
 [MH
+
] 
212.0286, found 212.0286.  
 
(8) 2-(2-(2-azidoethoxy)ethoxy)ethanamine 
Compound 7 (950 mg, 4.5 mmol) was mixed with NaN3 (877 mg,13.5 mmol) in 10 mL 
water and heated to 80 ˚C for 15 hrs. Then the pH of the solution was tuned with solid NaOH to 
be pH 12 and the aqueous mixture was extracted with diethyl ether. The organic layer was 
concentrated to give the desired product as light yellowish oil (503 mg, 64% for the last two 
steps). 
1
H-NMR: CDCl3, 500MHz, δ=1.79 (s, 2H), 2.88 (s, 2H), 3.39~3.41 (t, 2H), 3.52~3.54 (t, 
2H), 3.63~3.70 (m, 6H). 
13
C-NMR: CDCl3, 125.6 MHz, δ=41.7, 50.7, 70.1, 70.3, 70.7, 73.4. 
HRMS calculated for C6H15NO3
+
 [MH
+
] 175.1195, found 175.1192. 
 
(9) 5-(3-(2-(2-(2-azidoethoxy)ethoxy)ethyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-
yl)benzoic acid 
Compound 8 (35 mg, 0.20 mmol) was dissolved in 10 mL water with 5% K2CO3. FITC (50 
mg, 0.13 mmol) was added to the solution and kept stirring at room temperature overnight. The 
reaction solution was tuned to pH 1 with HCl before all the solvents were evaporated. The 
product was loaded onto a silica gel column and eluted with ether containing 5% acetic acid 
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followed by 10% methanol in diethyl ether containing 5% acetic acid. 
1
H-NMR: 
CD3OD:CD3COOD (95:5), 500MHz, δ=1.95~1.97 (m, 1H), 3.35~3.37 (m, 2H), 3.65~3.69 (m, 
6H), 3.71~3.73 (t, 2H), 3.83, (s, 2H), 6.54~6.56 (m, 2H), 6.68~6.69 (m, 4H), 7.15~7.16 (d, 1H), 
7.77~7.79 (d, 1H), 8.16~8.17 (d, 1H). 
13
C-NMR: CD3OD:CD3COOD (95:5), 125.6 MHz, δ=45.6, 
51.9, 71.2, 71.6, 71.5, 103.7, 111.7, 114.0, 125.9, 129.2, 130.5, 154.4, 161.8, 171.4. HRMS 
calculated for C27H26N5O7S
+
 [MH
+
] 564.1553, found 564.1557. 
The FITC conjugate of cLac-2 (cLac-2-Fl) was synthesized through click chemistry (Scheme 
1-3). cLac-2-Pra (500 μL of 1 mM stock solution in DMSO) and Compound 9 (40 μL of 13.5 
mM stock solution in methanol) were diluted into 1 mL tBuOH:DMF (1:1) mixture. Ascorbic 
acid (10 μL of 500 mM stock) and CuSO4 (10 μL of 500 mM stock) were sequentially added into 
the reaction mixture.  The reaction was allowed to proceed with shaking for 24 hrs. The product 
was purified through RP-HPLC (C18 column) and confirmed by analytical LC-MS. Fluorescent 
labeling of the linear peptide (Lac-linear-Pra) was accomplished by following the same protocol 
to give Lac-linear-Fl, which is used as a negative control in the cell imaging experiments.   
cLac-2-Fl,  calculated molecular weight: 1949 Da, found 1933 Da   
Lac-linear-Fl,  calculated molecular weight: 2008 Da, found 1992 Da   
The molecular weights were found to be 16 units less than expected as a result of hydrolysis 
of the thiourea moiety to urea. The hydrolyzed products displayed fluorescence profiles 
essentially identical to fluorescein and were used for the cell staining experiments (section VI).  
The alternative way of labeling cLac-2 is using Cys and maleimide conjugation. In the 
synthetic route with the native chemical ligation method, a Cys has been introduced onto the 
glycine linker I. The fluorophore Alexa fluor® 488 C5 maleimide was conjugated onto the Cys 
handle when it is mixed in a 1:1 ratio with the peptide at room temperature, in pH 7.5, 50 mM tris 
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buffer. The fluorophore conjugated peptide (cLac-Alexa) was purified through prep-HPLC, can 
characterized by LC-MS. 
cLac-Alexa,  calculated molecular weight: 2145 Da, found 2147 Da   
(The ~2 Da difference is within the error range of software calculation from multicharged species) 
 
IV. Liposome preparation 
Dansyl labeled 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) was 
synthesized according to the reported protocol
83
. Briefly, POPE (50 mg, 0.07 mmol), dansyl 
chloride (18 mg, 0.07mmol) and triethylamine (0.1 mL, 0.7 mmol) were mixed in 1 mL 
chloroform. The mixture was kept stirring in the dark. The reaction was monitored with TLC and 
completed in 6 hrs. The product was washed with Na2CO3 and extracted with dichloromethane, 
and then purified with silica chromatography, eluted with 4:1 dichloromethane and methanol. The 
identity and purity of the product were confirmed with NMR and ESI-MS. 
1
H-NMR: CDCl3, 
500MHz, δ=0.86~0.89 (m, 6H), 1.20~1.33 (m, 44H), 1.48 (m, 4H), 1.95~2.01 (m, 4H), 2.17~2.18 
(m, 4H), 2.83 (s, 6H), 3.18 (s, 2H), 4.01~4.10 (m, 5H), 4.30 (s, 1H), 5.23 (s, 1H), 5.30~5.33 (m, 
2H), 7.08~7.96 (d, 1H), 7.39~7.47 (m, 2H), 8.18 (s, 1H), 8.30~8.32 (d, 1H), 8.43~8.44 (d, 1H). 
ESI-MS calculated for C50H87N2O10PS [M+] 950.6, found 950.8. 
Liposomes were prepared by dissolving and mixing the desired phospholipids in chloroform. 
After evaporating chloroform, the residue was suspended in 50 mM Tris buffer, pH 7.4. The lipid 
suspensions were treated through 20 cycles of “freeze-and-thaw” process, and extruded 21 times 
through a membrane with diameter of 100 nm. To obtain homogeneous liposome samples, the 
extruded liposomes were passed through a gel filtration column (ÄKTA FPLC with Hiload
TM
 
16/60 Sephacryl
TM
 S-500 HR prep grade Column). For each liposome sample, the center fraction 
of its elution peak was collected and used for the peptide binding experiments. 
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The concentrations of liposome stocks were characterized via the Stewart Assay followed by 
reported protocol.
84
 This colorimetric method is based on the complex formation between 
phospholipids and ammonium ferrothiocyanate. Briefly, 2 mL of phospholipid solution in 
chloroform with 2 mL of 0.1M NH4Fe(SCN)4 in aqueous solution was mixed and shaked for 2min. 
The mixture was then centrifuged for 5 min at 2000 rpm. The UV absorption of the chloroform 
solution of the lipids was measured at 465 nm. The concentrations of the lipids were calculated 
with the reported extinction coefficient of PC 7960 M
-1
cm
-1
 and PS 6480 M
-1
cm
-1
.  
The size distribution of each liposome sample was characterized with a dynamic light 
scattering instrument (Dynapro
TM
 NanoStar, Wyatt Technology Corp., Santa Barbara, CA). The 
instrument setup used the standard PBS parameters: refractive index @589 nm & 20 
○
C is 1.333, 
viscosity is 1.019 cp, Cauchy coefficient is 3119 nm
2
. Data were acquired in auto-attenuation 
mode, and processed with DYNAMIC V6
TM 
software. The diameters of all liposomes were found 
to fall into the narrow range of 100~150 nm. (Figure 1-25) 
 
Figure 1-25. Size distribution of liposomes, measured with dynamic light scattering. 
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V. Liposome binding assay for the cLac peptides 
The liposome binding of the cLac peptides were evaluated by monitoring the sensitized 
dansyl emission upon addition of the peptides. The experiments were carried out on a 
SpectraMax M5 plate reader (Molecular Devices, Inc., Sunnyvale, CA) with a quartz cuvette of 
10 mm path length. The samples were excited at 280 nm and their emission was monitored from 
320 nm to 530 nm. All peptides were dissolved in DMSO to give a 0.8 mM stock. All tests were 
done with the total lipid concentration of 100 μM. An increasing amount of peptide of interest 
was titrated into the liposome solutions and the fluorescence emission was recorded. The dansyl 
emission intensity at 520 nm was plotted against peptide concentration to give the binding curves 
(Figure 1-15 C, Figure 1-16 A and Figure 1-19). 
 
VI. Cell culture experiments 
The stock concentrations of the FITC labeled peptides in PBS buffer were measured by 
recording the UV-Vis absorbance at 490 nm (reported  = 71,000 M-1•cm-1 on manufactory’s 
website). 
HeLa Cells 
HeLa cells were maintained in DMEM/High glucose with 10% FBS and 1% Pen/Strep at 37 
o
C, 5% CO2 and passed for less than 20 generations.  For imaging, cells were cultured to ~ 80-90% 
confluence on 20 cm Petri dishes. To induce apoptosis, cells were treated with 1 M 
staurosporine (STS) and incubated at 37 
o
C, 5% CO2. After 3 hours, the medium was aspirated 
and cells were gently washed once with PBS before 2 ml of 0.25% Trypsin-EDTA was added to 
harvest cells. After incubating at 37 
o
C, 5% CO2 for 3 minutes, 8 ml of DMEM media was added 
and cells were pelleted and washed with PBS twice. Then, cells were resuspended in PBS (or 1  
AV (annexin V) binding buffer for samples stained with AV-FITC) to reach the concentration of 
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10
6
 cells/ml. 200 l aliquots of the cell suspension were transferred into eppendorf tubes and 
mixed with cLac-2-Fl (200 nM) or AV-FITC (30 nM). PI (0.5 M) was included in all samples to 
monitor non-apoptotic cell death. The mixtures were incubated for 15 mins at R.T. in the dark. 
Then cells were pelleted and washed twice with PBS for cLac-2-Fl staining or the AV binding 
buffer (1x) for AV-FITC staining. After washing, the cells were resuspended into 100 l of PBS. 
For fluorescence microscopy imaging, 50 l of the cell suspension were transferred into the 
chamber made by two double-sided tapes, a cover glass (Fisherbrand, 2222-1.5) and a slide 
(Fisherfinest premium, 3 11mm). The open edges were sealed with VALAP. Images were 
taken on a Zeiss Axioplan 2 microscope equipped with filters that allowed detection of FITC 
(488nm excitation, 515-520nm emission) and PI (546nm excitation, 580-640 emission). A 20  
dry objective (Plan-NeoFluar, Zeiss) was used. Phase contrast images were taken by using the 
channel with polarized halogen light. All images were captured (time of exposure: 2.5 s for FITC 
and 1.0 s for PI), colored by OpenLab 5.5.2 and processed in Photoshop to increase the contrast. 
All images were processed following the same protocol.   
HeLa cells were co-stained with annexin V and PI as positive controls and the results are 
shown in Figure 1-20. As a negative control, the cells were stained with Lac-linear-Fl (Figure 1-
21). The results show minimal staining of STS-(un)treated cells by this linear peptide, indicating 
the cyclic design of cLac is essential for PS recognition.  
 
Jurkat Cells 
Jurkat cells were grown and maintained in RPMI 1640 media with 10% FBS and 1% 
Pen/Strep at 37 
o
C, 5% CO2 and passed for less than 20 generations.  The cell viability and 
density was checked and counted daily by using 0.2 M trypan blue as a viability testing dye on a 
hemocytometer. On the day of staining and imaging, the cells were cultured to a density of 
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1.51062.0106 cells/ml in a Corning cell culture flask (with vent cap). To induce apoptosis, 
cells were treated with 10 M camptothecin (CPT) and incubated at 37 oC, 5% CO2. After 4 
hours, the cells were washed twice with PBS buffer and resuspended in PBS (or 1x AV binding 
buffer for samples involving AV-FITC) at a concentration of 1  106 /ml. The dye staining and 
microscopy imaging were carried by following the same protocol as the HeLa cells.   
For flow cytometry analysis, Jurkat cells were cultured and treated with CPT as described 
above. Then the cells were resuspended in PBS (or 1  AV binding buffer for samples involving 
AV-FITC) at a concentration of 1  106 /ml. The cells were diluted five times and mixed with 
cLac-2-Fl (50 nM) and AV-FITC (15 nM) respectively. The mixtures were incubated for 15 mins 
in dark at room temperature before flow cytometry analysis. The experiments were carried out on 
a BD FACSAria cell sorter (BD Biosciences, San Jose, CA). Data analysis was performed with 
Flowjo (Tree Star, Inc., Ashland, OR) and Origin (OriginLab Corp., Northampton, MA).  
 
VIII. Evaluation of the calcium dependence of annexin V 
We explicitly evaluated the calcium dependence of annexin V by using flow cytometry and 
microscopy (Figure 1-24). Consistent with the previous report,
85
 the potential of annexin V to 
report apoptosis is heavily dependent on calcium concentration. In sharp contrast to with calcium, 
annexin V failed to stain the CPT-treated Jurkat cells without calcium addition, as shown 
consistently by both flow cytometry and microscopy. The calcium dependence makes it less ideal 
as a quantitative biomarker for cell death.   
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Chapter 2. Study of Apoptotic Cell Membrane (ACM) Permeant Molecules 
 
2.1 Introduction 
The importance of developing noninvasive imaging techniques for apoptosis has been 
discussed in the introduction part of chapter 1.  There are a number of strategies for detecting 
apoptosis in vitro, including imaging agents based on proteins that specifically target membranes 
that contain phosphatidylserine (PS). However,  it has been challenging to adapt them to 
noninvasive imaging in the clinic. These proteins have their intrinsic limitations mainly derived 
from their size and lack of proteolytic stability. For example, a radio-labeled annexin V was 
shown to be problematic for in vivo imaging due to poor tissue penetration and a slow clearance 
rate. 
86, 87
 These limitations, which are characteristic of large proteins, could be potentially 
circumvented by low-molecular weight agents selectively labeling apoptotic cells.
88
 
In the efforts to develop small molecule biomarkers for apoptosis, several characteristic 
features of apoptotic cells are being targeted including surface-exposed PS
66, 68, 89-91
 and caspase 
activity
92-94
. Smith et al. has developed a series of annexin V mimicking small molecules that 
bind the PS headgroup through coordination with two Zn
2+ 
cations. However, as annexin V, these 
small molecules are limited by the Zn
2+
 concentration dependent binding mechanism. 
66, 89
 Since 
caspase activation is a key event in apoptosis, activated caspases have been targeted for imaging 
apoptotic cells. A general strategy to target caspase activities is to attach a fluorophore and a 
quencher on short peptide sequences containing a caspase-sensitive site.
92, 93
 Some of the caspase 
activity probes are commercially available as benchtop kits for staining apoptotic cells. However, 
the caspase substrates may be nonspecifically degraded in the cell and caspase activation does not 
necessarily correlate to apoptosis. It has been observed in inflammation, as well as in cell 
proliferation, differentiation and migration.
95, 96
 Furthermore, caspase activation during apoptosis 
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is transient, so the timing of the assay need to be empirically estimated, which makes the data 
quality highly dependent on the operator. 
97
 
Besides caspase activation and PS exposure, several reports in literature have indicated that 
apoptotic cells differ from healthy cells in membrane permeability.
98-100
 In contrast to necrotic 
cells, the apoptotic cell membrane (ACM) remains intact through the early stages of apoptosis. 
However, several small molecules have been observed to be selectively transported across the 
ACM.
88, 101
 Since there are only a few examples and these discoveries are relatively isolated, the 
structural characteristics related to the ACM permeability still remain to be elucidated. 
Three groups of these molecules that afford specific entry into apoptotic cells are reviewed 
here. The structures of these molecules and the hypothesized mechanisms are discussed.  
1) Dicarboxylate derivatives 
γ-carboxyglutamic-acid (Gla, Figure 2-1 A) has been considered responsible for mediating 
membrane binding of the Gla rich domain in many anionic membrane binding proteins, including 
the clotting factors II, VII, IX, and X, and the anticoagulant protein C and S.
102, 103
 A molecule (2-
(5-fluoro-penyl)-2-methyl-malonic acid, ML-10, Figure 2-1 B) mimicking Gla has been observed 
capable of selective entry into apoptotic cells.
100
 In the structure of ML-10, the alkyl-malonate 
group has been proven to be a key structural moiety (as it is in Gla) enabling the binding to the 
anionic cell membrane, and the alkyl chain renders the molecule amphipathic for lipid bilayer 
insertion.  
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Figure 2-1. The structure of A) γ-carboxyglutamic-acid (Gla), and B) 2-(5-fluoro-penyl)-2-methyl-malonic 
acid (ML-10). 
More interestingly, ML-10 uptake is found to correlate synergistically with intracellular 
acidification and plasma membrane depolarization. Cell acidification is a characteristic 
phenomenon of apoptosis that occurs at the early stage of apoptosis.
104
 The pH can drop 0.4~0.9 
units during the process.
105
 A pH dependent cell uptake of ML-10 is observed. It is hypothesized 
that the acidic extracellular environment causes single protonation of the two carboxylic acids 
(pKa 2.8 and 5.8) of ML-10, forming an acid-anion dimer with an internal hydrogen bond. This 
internally hydrogen bonded structure reduces charge density compared to the dicarboxylates, 
possibly facilitating ML-10 partitioning into the cell membrane. 
106
 
Another hallmark of early stage apoptotic cells is the permanent plasma membrane 
depolarization (PMD).
107
 Healthy cells maintain an electric potential gradient across the plasma 
membrane. Upon apoptosis activation, the cell loses its cellular ion homeostasis and the 
membrane loses its potential gradient. The depolarized membrane appears to facilitate the 
membrane translocation of ML-10 through unknown mechanisms. ML-10 was incubated with 
Jurkat cells that were depolarized by introducing high concentration of extracellular potassium
108
, 
and the results showed that cell uptake of the molecule and membrane depolarization occurred 
simultaneously.  
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2) Monomeric cyanine dyes 
Two of the earliest ACM permeant molecules belong to a family of DNA-intercalating dyes 
developed by Molecular Probes®. As monomeric cyanine derivatives, these molecules share a 
similar structural moiety and have been used as the replacement of ethidium bromide in agarose 
gels for their ability to stain DNA fragments with a higher signal/noise ratio. In contrast to most 
of these dyes, which are impermeant to the integrate cell membrane, YO-PRO®-1 and TO-
PRO®-3 (Figure 2-2) show selective membrane penetration for apoptotic cells at early stage. 
98
 
 
 
Figure 2-2. Structure of DNA-intercalating dyes YO-PRO-1, TO-PRO-3 and Propidium iodide 
 
Recent research by Chekeni et al. showed that the activation of the plasma membrane channel 
pannexin 1 (PANX1) is related to ACM permeability. For YO-PRO-1 and TO-PRO-3, the cell 
uptake was PANX1 dependent.
109
 More interestingly, another DNA intercalating molecule, 
propidium iodide (PI), with a similar size and charge, is unable to be internalized.  This suggests 
PANX1 is one of the factors that are responsible for the ACM permeability, but it is unclear about 
its mechanism of selectivity. There is no evidence on whether PANX1 is responsible for the 
ACM permeability of other small molecules such as ML-10. 
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3) Dansyl-derivatives 
Some dansyl derivatives have been reported capable of penetrating through the ACM. (Figure 
2-3) The membrane permeability of these molecules is correlated to caspase activity, but the 
exact mechanism is still unknown. 
99, 101, 110
 
 
Figure 2-3. Dansyl derivertives that are apoptotic cell permeant. A) N’,N-didansyl-L-cystine; B) 5-
(dimethylamino)-1-naphthalene-sulfonylethylfluoroalanine (NST-732); C) 4-(5-(dimethylamino) 
naphthalene-1-sulfonamido)-3-(4-iodophenyl)-butanoic acid (DNSBA); D) (E)-5-(dimethylamino)-N'-(4-
fluorobenzylidene)naphthalene-1-sulfonohydrazide.  (DFNSH) 
It is still not yet clear whether a common mechanism for ACM permeability exists for these 
molecules, since they do not share any structural similarity. On the other hand, for molecules that 
do share similar structures, they behave differently in permeating through the ACM. A good 
example is YO-PRO and PI. It remains to be elucidated whether there is a common structural 
feature that enables these molecules to selectively penetrate through the ACM.  
 
2.2 Selective entry into apoptotic cells by fluorescein derivatives 
We have discovered a group of fluorescein derivatives affording similar ACM permeability 
as ML-10. More interestingly, the ACM permeability extends to a group of derivatives based on 
the fluorescein and fluorescein analogue scaffolds, including variation on charges and sizes. We 
will expect that this research will expand the pool of small molecules with ACM permeability, 
and they can be further developed into novel non-invasive imaging probes for apoptosis. 
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2.2.1 Fluorescein gains apoptotic cell entry upon simple derivatization 
Dyes of the fluorescein family 
are among the most widely used 
fluorescence reporters in chemical 
and biomedical research. The 
parent compound fluorescein is 
not known to differentiate healthy 
and apoptotic cells. Indeed, when 
fluorescein is subjected to flow 
cytometry analysis of Jurkat cells 
(Figure 2-4 A), the same degree of 
staining was observed for the cells 
treated with and without 
camptothecin (CPT, a 
topoisomerase inhibitor known to 
induce apoptosis of Jurkat cells).
89
 In contrast, the simple derivative Fl-EA (Figure 2-4 
B) selectively stained the cell sample with CPT treatment but not the one without. 
Specifically, Fl-EA afforded essentially no staining of the untreated cells, but identified 
two populations for the CPT-treated sample. The population displaying higher 
fluorescence intensity, presumably the apoptotic cells, constituted ~48% of the total cell 
population. This agrees nicely with the positive control, in which a FITC (fluorescein 
isothiocyanate) labeled annexin V (AV-FITC) was used as an apoptosis reporter (Figure 
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Figure 2-4. Flow cytometry analysis of (A) fluorescein 
and (B) the derivative. (C) Fl-EA FITC labeled Annexin V 
(AV-FITC) was used as a positive control. Jurkat cells 
with (left) and without (right) CPT treatment were stained 
with the three agents respectively. x-axis: the FITC 
channel; y-axis: the PI (propidium iodide) channel. 
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2-4 C). Also similar to AV-FITC, the Fl-EA stained cells showed no fluorescence 
emission of propidium iodide (PI, the y-axis), a membrane impermeant DNA intercalator. 
This observation suggests that Fl-EA stains early stage apoptotic cells.   
 
Figure 2-5. Costaining apoptotic cells with Fl-EA and AV-PE. A) Flow cytometry analysis of Jurkat cells 
in presence of Fl-EA and AV-PE; x-axis: the FITC channel; y-axis: the PE channel. B) Confocal image of 
AV-PE fluorescence. C) Confocal image of Fl-EA fluorescence. D) Overlay of B and C.  
The specificity of Fl-EA for apoptotic cells were further validated through a costaining 
experiment with the R-phycoerythrin labeled annexin V (AV-PE, yellow emission). In 
presence of both Fl-EA and AV-PE, essentially all stained cells converged in the upper 
right quadrant (Figure 2-5 A) indicating that each of these cells was stained with AV-PE 
and Fl-EA simultaneously. The flow cytometry result was further validated with confocal 
microscopy analysis. As expected, the microscopic image revealed the membrane 
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localization of AV-PE on the CPT-treated cells (Figure 2-5 B). In contrast, Fl-EA was 
clearly internalized and evenly distributed in the cytoplasm (Figure 2-5 C, D). 
Collectively these results strongly support the hypothesis that early apoptotic cells 
display altered membrane permeability to allow entry of the fluorescein derivative Fl-EA.  
Why is the unmodified fluorescein unable 
to differentiate apoptotic and healthy cells? In 
flow cytometry analysis (Figure 2-4), the 
healthy cells incubated with fluorescein 
displayed a higher fluorescence readout than 
those treated with Fl-EA, suggesting certain 
mechanisms of nonspecific staining. 
Consistent with the flow cytometry results, 
confocal imaging of the fluorescein-treated 
cells showed brighter fluorescence inside the 
cells in comparison to Fl-EA staining (Figure 
2-6 A, C). These observations suggest that 
fluorescein permeates through both healthy 
and apoptotic cell membranes. For Fl-EA, the 
simple modification of fluorescein prohibits 
entry into healthy cells. For the cells without CPT treatment, an interior darker than the 
extracellular background was displayed, indicating that Fl-EA is incapable of permeating 
through the membrane of healthy cells. (Figure 2-6 D) Additionally, the apoptotic cell 
A B
DC
Figure 2-6. Comparison of fluorescein (A, C) 
and Fl-EA (B, D) in staining Jurkat cells with 
(A, B) and without CPT (C, D) treatment. In 
contrast, fluorescein shows no selectivity for 
cells with and without CPT treatment. For 
CPT-untreated cells, brighter fluorescence was 
observed with fluorescein than Fl-EA (C vs. 
D), suggesting that fluorescein is capable of 
entering healthy cells as well. 
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stained with Fl-EA showed brighter interior than fluorescein stained cells, indicating 
some degree of accumulation effect on Fl-EA uptake. (Figure 2-6 B) From the 
preliminary analysis, the simple modification of fluorescein prevented healthy cell 
membrane and enhanced the apoptotic cell uptake, thereby affording the specific staining 
of apoptotic cells by Fl-EA.  
 
2.2.2 Expanded structural scope for apoptotic cell permeant dyes 
Further exploration revealed a number of derivatives of commonly used dyes that are capable 
of selective entry into apoptotic cells (Figure 2-7A). For example, reacting FITC with a long-
chain amine yields the compound Fl-PEG3-N3, which similar to Fl-EA readily stains the 
apoptotic cells. Similarly, two derivatives of Alexa Fluor

 488 (Alexa-Cys and Alexa-
Cysteamine) successfully label the apoptotic population of Jurkat cells upon CPT treatment. 
These three compounds display a net charge of -1, -2, and -1 respectively.  
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Figure 2-7. Flow cytometry analysis of the FITC and Alexa Fluor 488 derivatives in staining Jurkat cells. 
The upper panel displays the results for CPT treated cells; the lower panel presents the results for cells 
without CPT treatment. The corresponding structure of the dye molecules are displayed on top of the flow 
cytometry results.  
 
An ethanolamine derivative of rhodamine B isothiocyanate (Rh-EA, net charge zero) 
preferentially stains apoptotic cells as well (Figure 8). Rhodamine B behaves similar to 
fluorescein, lightly staining both healthy and apoptotic cells. In contrast to Fl-EA, there is minor 
cell entry into the CPT untreated cells for Rd-EA, but the staining with CPT treated cells is much 
brighter, indicating more cell entry and a similar accumulation mechanism. 
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Figure 2-8. Confocal microscopy analysis of Rhodamine B (A, B) and Rh-EA (C, D) staining Jurkat cells.  
A, C: CPT treated cells; B, D: CPT untreated cells. After dye staining, the cells were pelleted and 
resuspended in a dye-free PBS buffer before microscopy analysis. 
 
This group of apoptosis markers, although sharing the same carbon skeleton, displays various 
functional groups and a net charge ranging from -2 to 0. Their similar cell entry behavior suggests 
that the functional group and net charge do not play a role in determining apoptotic cell 
membrane permeability. The scope of apoptotic cell-permeant molecules was further explored by 
conjugating cyclic peptides of various sizes onto the fluorophores. Specifically, I prepared three 
conjugates of Alexa Fluor

 488 that carry cyclic peptides of five, eight, and eleven residues 
respectively (Figure 2-9). These cyclic peptides differ only in the number of alanine residues 
included in their sequence. These Alexa-peptide conjugates were designed to display the same net 
charge as Alexa-Cysteamine. However, in sharp contrast to Alexa-Cysteamine, even the 
conjugate with the smallest cyclic peptide was unable to enter apoptotic cells, suggesting a rather 
narrow window of molecular size is allowed for apoptotic cell entry.  
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Figure 2-9. Comparison of Alexa-Cysteamine and Alexa-peptides suggesting molecular size as a 
determining factor for apoptotic cell entry. The flow-cytometry results: left column, Jurkat cells with CPT 
treatment; right column, Jurkat cells without CPT treatment. 
 
2.2.3 Mechanistic study on apoptotic cell entry of Alexa-Cys 
The mechanism of cell entry of these dye derivatives was also investigated by varying the 
concentration used to stain Jurkat cells. At 50, 100, 200, and 500 nM concentrations, Alexa-Cys 
identified essentially the same percentage of cells that were at early stages of apoptosis. 
Interestingly, increasing the concentration of Alexa-Cys afforded increased fluorescence intensity 
of the apoptotic population (Figure 2-10), suggesting that cell entry of Alexa-Cys might be 
through passive diffusion driven by the concentration gradient. More interestingly, the membrane 
permeability of Alexa-Cys appeared to be irreversible:  the fluorescence staining of apoptotic 
cells remained unchanged upon multiple washes with the fluorophore-free medium (Figure 2-
11). This observation indicates the fluorophore is incapable of escaping after its entry into 
apoptotic cells.  
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Figure 2-10. Flow cytometry analysis of apoptotic cells stained with Alexa-Cys at varied concentrations. 
Alexa-Cys labels the same percentage of the cell population at all concentrations. The mean fluorescence 
intensity of the apoptotic population increases with Alexa-Cys concentration (inset), suggesting a passive 
diffusion mechanism of cell entry driven by the concentration gradient. 
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Figure 2-11. Irreversible cell entry of Alexa-Cys. Washing multiple times did not reduce the fluorescence 
intensity of the apoptotic cells stained with Alexa-Cys. Top row: CPT treated cells; bottom row, CPT 
untreated cells.  The cells were stained with 500 nM Alexa-Cys and 0.5 M PI for 15 mins. In each 
washing step, the cells were incubated in fresh PBS buffer for 20 mins to allow the small molecule dyes to 
reach equilibrium of distribution.   
 
2.3 Conclusions 
Currently, only a limited number of small molecules are known to selectively permeate into 
apoptotic cells. Our work represents the first systematic investigation on the structure-
permeability relationship for apoptosis-specific molecules. The results show that the membrane of 
apoptotic cells grants entry to small molecules of varied structure and charge, but appears to have 
a relatively stringent requirement on molecular size. Importantly, I demonstrate for the first time 
that simple modification enables several members of the fluorescein family to gain selective entry 
into apoptotic cells, which significantly expands the arsenal of low-molecular weight reporters of 
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apoptotic cell death. I expect that the new findings described here will greatly contribute to the 
design of small molecule agents that enable noninvasive imaging of apoptosis in living 
organisms.  
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Experimental Procedures 
 
I. General methods 
Alexa Fluor® 488 C5 maleimide and fatty acid-free bovine serum albumin (BSA) were 
purchased from Invitrogen (Carlsbad, CA). Fluorescein, Fluorescein 5(6)-isothiocyanate, 
Rhodamine B isothiocyanate and other common chemicals were purchased from Sigma Aldrich 
(St. Louis, MO). PBS buffer, RPMI 1640 media, and Pen/Strep were purchased from Thermo 
Scientific (Amarillo, TX). Camptothecin (CPT) was purchased from MP Biomedicals LLC 
(Solon, OH). PE-labeled and FITC-labeled annexin V (AV-PE and AV-FITC), together with 
propidium iodide (PI), were purchased as an apoptotic cell detection kit from BD Biosciences 
(San Jose, CA). VALAP was prepared in house by melting and mixing equal amounts of Vaseline, 
Lanolin and paraffin wax, which were purchased from a local CVS Pharmacy. MS data for the 
characterizations of the molecules were generated by the Boston College Mass Spectrometry 
center. The concentration measurements were performed on a NanoDrop 2000c UV-Vis 
spectrometer from Thermo Scientific (Wilmington, DE). Flow cytometry data were generated by 
a BD FACSAria cell sorter from BD Biosciences (San Jose, CA). The confocal microscopy 
images were generated from a Leica SP5 confocal fluorescence microscope from Leica 
Microsystems Inc. (Buffalo Grove, IL) 
 
II. Synthesis, purification and characterization 
The molecules Fl-EA, Rh-EA, Fl-PEG3-N3 were made by conjugating the substituent 
precursor (ethanolamine or amino-PEG3-azide) onto the corresponding dye following the 
protocol that has been previous published (Scheme 2-1).
1
 Alexa-Cys, Alexa-Cysteamine and the 
Alexa-peptides were made by conjugating the cysteine, cysteamine or the peptides onto the 
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corresponding dye following the Invitrogen protocol for Alexa fluor-C5-Maleimide labeling 
(Scheme 2-1). The compounds were purified by RP-HPLC (Waters Prep LC, Jupiter C18 Column) 
and characterized by LC-MS to verify the identity and purity. 
Table 2-1. Mass spectrometry characterization of the molecules. 
Molecule Name Formula Weight Calculated MS Found 
Fl-EA 450.09 451.1 [MH
+
] 
Fl-PEG3-N3 563.15 564.15 [MH
+
] 
Rd-EA 561.25 561.1 [M
+
] 
Alexa-Cys 819.12 820.6 [MH
+
] 
Alexa-Cysteamine 775.13 776.4 [MH
+
] 
Alexa-peptide 1 1243.34 1244.4 [MH
+
] 
Alexa-peptide 2 1456.45  1457.2 [MH
+
] 
Alexa-peptide 3 1669.56 1670.3 [MH
+
] 
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Scheme 2-1. Synthesis of the dye derivatives.  A. direct conjugation of ethanolamine and PEG3-N3 onto 
FITC. The synthesis of Rh-EA followed the same protocol and is not explicitly shown here. B. direct 
conjugation of cysteamine, cysteine, and three cyclic peptides onto Alexa fluor 488 C5 maleimide.  
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III.  Cell culture and sample preparation 
Jurkat cells were grown and maintained in RPMI 1640 media with 10% FBS and 1% 
Pen/Strep at 37 
o
C, 5% CO2 and passed for less than 20 generations.  The cell viability and 
density were checked daily by using 0.2 M trypan blue as a viability testing dye and counting 
cells on a hemocytometer. Jurkat cells were cultured to a density of 11062106 cells/mL in 
Corning cell culture flasks (with vent cap). To induce apoptosis, cells were treated with 15 M 
CPT for 4 hours at 37 
o
C, 5% CO2. The cells (both CPT treated and untreated) were pelleted, 
washed twice with the PBS buffer, and resuspended at a density of 1  106 cells/mL in the PBS 
buffer for small molecule dyes or in 1  AV binding buffer for samples treated with AV-FITC. 
Aliquots of 200L (2 105 cells) were transferred to 500 L eppendorf tubes, to which was added 
2 L AV-FITC stock (~ 15 nM according to the instruction manual) or a small molecule dye (500 
nM unless indicated otherwise). All cell samples also included 0.5 M PI in order to monitor 
non-apoptotic cell death. The cell suspension was gently vortexed and incubated in the dark at 
room temperature for 15 mins prior to flow cytometry analysis.  
 
Flow cytometry. To minimize the background emission, the cell samples stained with the 
small molecule dyes were washed twice with PBS buffer before they were transferred to a 5 mL 
cell culture tubes. The control sample stained with AV-FITC was directly transferred into the 
tube without washing. After the transfer, the cell samples were immediately prepared for flow 
cytometry analysis. The flow cytometry data were generated by a BD FACSAria cell sorter, with 
data shown for the appropriate channels according to fluorophores used.  
 
Confocal microscopy. To prepare slides for fluorescence microscopy imaging, 50 l of the 
cell suspension was transferred into the chamber made by double-sided tapes, a cover glass 
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(Fisherbrand, 2222-1.5) and a slide (Fisherfinest premium, 3 11mm). The open edges were 
sealed with VALAP. Images were taken on a Leica SP5 confocal fluorescence microscope (Leica 
Microsystems Inc., Buffalo Grove, IL) with filters that allowed detection of FITC (488 nm 
excitation, 496 nm – 564 nm emission), PI (543 nm excitation, 605~768 nm emission),  PE (488 
nm excitation, 575~656 nm emission) and Rhodamine (543 nm excitation, 600~696 nm emission). 
A 63 oil objective was used. Pictures were captured and processed by ImageJ (NIH Image). 
The costaining experiment with AV-PE and Fl-EA (Figure 2-5, main text) was carried out 
with 15 nM AV-PE and 500 nM Fl-EA. The cells were washed (with 1 x AV binding buffer) 
once for flow cytometry and twice for microscopy analysis.   
 
IV. Scope of dye derivatives that target apoptotic cells 
The cell staining results of four small molecules that behave similar to Fl-EA are presented in 
Figure 2-7, main text. The same protocol has been carried out for these molecules, including Fl-
PEG3-N3, Alexa-Cys, Alexa-Cysteamine and Rh-EA to stain CPT treated and untreated Jurkat 
cells. The flow cytometry results for these molecules (except for Rh-EA, which is explained in 
the next paragraph) were identical to each other, as well as to that of Fl-EA. 
Due to the only available excitation wavelength of the flow cytometer that can be used to 
excite Rh-EA is 488 nm, and the fluorescent intensity of Rh-EA excited at 488 nm is too low and 
the data is difficult to be interpreted, therefore we were unable to analyze Rh-EA with flow 
cytometry. Instead, the confocal microscopy images confirmed that Rh-EA can selectively stain 
the apoptotic cells. As a negative control, Rhodamine B displayed no selectivity.  
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V. Irreversible cell entry of the apoptosis markers  
Before preparing samples for flow cytometry, the Alexa-Cys stained cells were washed with 
PBS buffer for one, two and three times respectively. Each washing step included 20 mins 
incubation to ensure the small molecule to reach the equilibrium of distribution. (Figure 2-11.) 
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Chapter 3. Study of Aromatic-Fluorinated Aromatic Interactions in Peptide Systems 
 
3.1 Introduction 
Therapeutic proteins have been through a remarkable expansion in the last two decades, and 
have helped to advance the field of protein engineering.
111
 A protein’s function is dictated by its 
three dimensional, folded structure, which is based on the non-covalent interactions between 
amino acid side chains, such as hydrogen bond, salt bridge and van der Waals interactions. 
Although nature has provided 20 amino acids to establish these interactions in proteins, they are 
usually not sufficient to gain desired structure stability and target specificity of protein drugs. For 
example, protein structure stability has always been a problem for protein therapeutics.
112
 In fact, 
the folded structures of most natural proteins are not stable, the average free energy of folding is 
about -5~10 kcal/mol.
113
 Therefore, protein therapeutics such as recombinant insulin require 
special storage or formulation to maintain the folded structure and activity. Protein engineering 
focuses on solving these problems by purposefully modifying proteins with chemical methods to 
enhance their clinical potential such as structure stability and target specificity. A useful strategy 
of protein modification is to incorporate unnatural amino acids into protein sequences.
114
  
Among all types of unnatural amino acids, the family of fluorinated amino acids has drawn 
much attention because of the special properties of fluorine, including its absence from biological 
systems, small size and high electronegativity.
115, 116
 
One advantage of incorporating fluorine into protein therapeutics is that fluorine is essentially 
absent from biology, so fluorinated proteins can serve as bioorthogonal probes in cells and living 
organisms with zero background. 
19
F NMR has become a powerful tool in protein structure 
analyses, even in living cells.
117
 Since 
19
F has similar sensitivity (86%) as proton in NMR 
spectroscopy, as well as a relatively broad range of chemical shifts, it could be used for detection 
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of subtle changes in the environment, such as monitoring the membrane insertion of a protein.
118
 
18
F has also been commonly used as a positron emission tomography (PET) probe because of its 
long half-life (110 min).
119
 PET produces a three dimensional image of biological processes in the 
body while other imaging techniques (e.g., as X-ray, CT and MRI) only show structural 
information. Therefore, PET provides a potential opportunity for using a 
18
F labeled protein to 
study its function in vivo.
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Another important advantage of using fluorinated amino acids in protein engineering is the 
small size of fluorine. The van der Waals radius of fluorine is only slightly larger than that of 
hydrogen (1.35 Å for F and 1.2 Å for H). Fluorine is often considered isosteric with hydrogen and 
introduces minor steric perturbation to protein structures.  
Finally, since fluorine is the most electronegative atom, a C-F bond has low polarizability. In 
fact, fluorocarbons are generally difficult to be solvated by either polar or non-polar solvents. 
This property of fluorocarbons has been exploited to enhance the hydrophobicity of amino acid 
side chains to give stabilized protein structures. 
116
  
Here I review previous investigations on fluorinated amino acids and their impact on protein 
stability and protein-protein interactions. The fluorination of aromatic residues results not only in 
hydrophobicity enhancement, but also alters electrostatic interactions with other residues in the 
protein context (see section 3.1.3 for details). These amino acids are less understood compared to 
fluorinated aliphatic amino acids. I focus on this part and then discuss my research on the 
aromatic-fluoroaromatic interactions in two different peptide model systems. The goal of my 
research is to understand the structural and energetic perturbations of fluorinated aromatic amino 
acids to protein stabilities. Ultimately, I aim to understand the fundamental principles of utilizing 
fluorinated amino acids in protein engineering for developing more stable and potent protein 
drugs. 
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3.1.1 Fluorinated aliphatic amino acids in peptide/protein engineering 
Fluorinated aliphatic amino acids have been extensively studied in the last decade and the 
hydrophobicity enhancement by fluorination is well known.
121
 For instance, fluorinated leucine 
and valine are more hydrophobic than their natural counterparts: the log P values of Leu and Val 
side chains are 2.50 and 2.08 and those of hexafluoro-Leu and Val side chains are 3.88 and 3.29 
respectively. The consequence of this hydrophobicity enhancement will be discussed below. 
 
1) Enhanced structure stability of fluorinated proteins.  
Examples of stabilizing protein structures by 
fluorinated aliphatic amino acids have been reported on 
various protein model systems and the energetic 
contributions of fluorinated amino acids to the protein 
stability have been extracted and compared. 
For example, Marsh, et al. have incorporated 
hexafluoro-Leu (hfLeu) into an antiparallel 4-helix 
bundle structure (Figure 3-1).
122
 There are six layers of 
Leu residues in the hydrophobic core of the helix bundle. 
Substituted with an increasing number of hfLeu, the 
stability of this complex increased. With two Leu residues 
substituted by hfLeu on each α-helix, the helix bundle 
was stabilized by -2.5 kcal/mol. Each hfLeu contributes about -0.3 kcal/mol to the increased 
folding free energy comparing to Leu. This number agrees well with the predicted value 
estimated from comparing the partitioning of the Leu and hfLeu side chain between n-heptanol 
and water (ΔΔG= -0.4 kcal/mol). 
Figure 3-1. α-helices bundle stability 
was enhanced as a function of the the 
degree of fluorination. 
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A similar stabilizing effect was also observed upon fluorination of the coiled-coil domain of 
the yeast transcription factor GCN4.
123
 Four Leu and three Val residues were substituted by 
trifluoro-Leu (tfLeu) and trifluoro-Val (tfVal) respectively. The fluorinated peptide dimer 
exhibited a stabilized structure with a higher folding free energy (-1.0 kcal/mol over the 
hydrocarbon counterpart). Each buried trifluoromethyl group enhanced the folding free energy by 
-0.08 kcal/mol, which was slightly lower than the result reported by Marsh (-0.15 kcal/mol per 
buried trifluoromethyl). The difference could be explained by the fact that the GCN4 peptides 
comprised a mixture of isostereomers, since the tfLeu and tfVal were racemic at γ-C and δ-C 
respectively. Tirrel and coworkers showed that substitution of the six core Leu residues by tfLeu 
in a de novo designed coiled-coil dimer resulted in an increased stability of -0.4 kcal/mol per 
trifluoromethyl group.
124
 Although the energetic contribution varies with the fluorinated amino 
acids and the protein context, the stabilization effect generally exists.  
 
2) Specific recognition between fluorinated proteins 
Due to their low polarizability, fluorocarbons are difficult to be solvated by either polar or 
nonpolar solvents and therefore tend to segregate from both aqueous and hydrophobic media. 
This phenomenon is often referred to as the “fluorous effect”125. Installation of fluorinated 
aliphatic residues at protein-protein interfaces could introduce a recognition mechanism 
orthogonal to those of natural proteins based on the “fluorous effect”. 
For example, Kumar et al. tested the selective assembly of a fluorinated helical peptide in 
aqueous solutions.
126
 By mixing the fluorinated monomer and its hydrocarbon counterpart, the 
mixture exclusively formed homodimers. It was suggested that the “fluorous effect” was the 
driving force for the selective association between fluorinated monomers. 
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Programming the association of membrane proteins in the lipid bilayer has proven difficult. 
Natural proteins prefer to recruit polar residues such as asparagine into the lipid bilayer, which 
participate in hydrogen bond formation to drive protein-protein associations.
127
 However, the 
incorporation of a hydrogen bond into the lipid bilayer in protein engineering may not achieve 
high specificity if there are other potential hydrogen bond partners in the biological system. In 
fact, the inter-helical hydrogen bonding of natural transmembrane proteins should be well 
regulated. Mutations on transmembrane helices with polar side chains that cause unregulated 
hydrogen bonding could be disastrous. For example, V659E mutation on Her2 transmembrane 
domain results in excessive dimerization due to the hydrogen bonding formation between the 
mutated glutamates and consequently triggers undesired downstream effects that can lead to 
cancer.
128
 The “fluorous effect” provides an orthogonal mechanism to mediate protein association 
even in the hydrophobic environment such as a lipid membrane. Kumar et al., incorporated 
fluorinated Leu into a de novo designed transmembrane peptide, which exists as monomeric 
helices in the lipid membrane.
129
 In contrast, the fluorinated peptide formed homodimers in the 
lipid-bilayer (Figure 3-2).  
 
Figure 3-2. Fluorinated transmembrane peptides tend to self-associate in the lipid bilayer, driven by the 
“fluorous effect”. Green: fluorine atoms; red: oxygen; blue: nitrogen; purple: peptide backbones. 19 
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3.1.2 Fluorinated aromatic amino acids in protein/peptide engineering 
1) Polar-π interactions 
There are three common geometries that a pair 
of aromatic molecules can adopt: face-face stacked, 
offset stacked and edge-face stacked (Figure 3-
3).
130
  
A benzene ring affords a negative potential on the π-cloud and positive potential on the edge 
of the hydrocarbon ring. This electron distribution, 
referred to as a quadrupole, allows benzene pairs 
to adopt the offset stacked or edge-face geometries, but not the face-face stacked geometry. For 
this reason, it is rare to find perfectly face-face stacked aromatic rings in a native protein. Offset 
stacked and edge-face geometries have been observed.
131, 132
 In native protein structures, most 
interacting aromatic pairs adopt geometries that fall between the edge-face and offset stacked 
geometries. 
Fluorination of an aromatic ring results in a redistribution of the electron density. For instance, 
perfluorobenzene affords the opposite distribution, have positive π-cloud and negative edges. The 
reversed quadrupole moments should allow benzene and perfluorobenzene to adopt favored face-
face stacked geometry due to the matching of complementary charge.
133, 134
 The two molecules 
mix readily and present an alternating arrangement in a face-face stacked geometry in the 
cocrystal structure.
135
 Furthermore, the quadrupole moment allows an aromatic molecule to 
engage in electrostatic interactions with a charge, a partial charge, a dipole, or a reversed 
quadrupole.
136
 These noncovalent interactions are collectively referred to as “polar-π” interactions. 
The influence of fluorination on the quadrupole moment of an aromatic ring highly depends 
on the degree and the position of fluorine substitutions. Figure 3-4 shows an electron potential 
Figure 3-3. Three typical modes of aromatic 
interactions in protein systems. 
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map for a variety of fluorinated phenyl rings with 
different fluorination patterns.
137
 Because of the 
electron withdrawing effect of fluorine, the higher 
degree of fluorination on the aromatic ring gives 
lower electron density on the π-cloud. For highly but 
not fully fluorinated phenyl rings, the partial positive 
charge on the remaining aromatic hydrogen is 
significantly enhanced. For example, the partial 
positive charge on the para-H (to the methyl group) 
of Zp (Figure 3-4) increased from +0.089 to +0.202 upon fluorination. Furthermore, fluorination 
alters the quadrupole moment. The influence of fluorination to a quadrupole-quadrupole 
interaction depends on the geometry of the interacting aromatic pairs.  Therefore it is necessary to 
catalog the geometries of aromatic interactions and then analyze the energetic consequence of 
introducing fluorinated aromatic side chains into each type of geometries. 
Table 3-1. Calculated interaction energies of benzene-perfluorobenzene pair 
As we discussed in the previous section, the opposite quadrupole moments allow benzene (-
29.0 x 10
-40
 C·m
-2
) and perfluorobenzene (31.7x 10
-40
 C·m
-2
) to adopt the face-face stacked 
geometry.
134
 Tsuzuki et al. investigated the influence of perfluorination on the quadrupole 
interactions of benzene pairs with CCSD(T) methods (Coupled-Cluster with Single and Double 
Figure 3-4. The electron potential map of 
selected fluorinated phenyl rings. 
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and Perturbative Triple excitations, Table 3-1).
138
 The most favored geometry is the offset face-
face stacked pair (ΔE=-5.38 kcal/mol), followed by the face-face stacked geometry (ΔE=-5.07 
kcal/mol). Both interactions are stronger than the offset stacked benzene rings (ΔE=-2.48 
kcal/mol). The two edge-face benzene-perfluorobenzene pairs are less stable than the edge-face 
benzene pair (-2.46 kcal/mol) mainly because the edge-face interaction is eliminated by 
fluorination either by reducing the electron density of the π-cloud donor (Table 3-1 c), or by 
replacing the partial positively charged hydrogen by the negatively charged fluorine (Table 3-1 d). 
This calculation predicts that perfluorination of aromatic rings engaging in edge-face interactions 
will result in reduced protein stability if only considering the electrostatic interactions. 
 
2) Introducing fluoroaromatic residues into proteins 
Fluorinated aromatic amino acids have been introduced into several protein systems, 
including single α-helices and more complicated systems with tertiary structure. However, the 
conclusions suggest that the effect of fluorination is highly context dependent. In some cases, 
destabilization is observed when fluorinated aromatic amino acids are incorporated. 
For example, Waters et al. incorporated 
interacting aromatic pairs into an α-helical 
peptide.
80
 The interactions between a 
phenyalalnine at the i position and four natural 
and unnatural aromatic side chains at the i+4 
position were investigated (Figure 3-5). The 
residues at the i+4 position include phenylalanine 
(F), homophenylalanine (hF), biphenylalanine 
(Bip), and pentafluorophenylalanine (Z). The 
Figure 3-5. (a) Helical wheel diagram indicating 
the relative positions of side chains in an α-helix. 
(b) Structures of hF, bF, and f5F. 
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interactions raised the stability of the α-helix by -0.1 to -0.8 kcal/mol (in comparison to the i & 
i+5 substitutions). The F-F pair was found to provide the greatest stability, which stabilized the α-
helix by -0.27 to -0.8 kcal/mol. The magnitude of the stabilization was close to hydrophobic 
interactions between aliphatic and phenyl side chain pairs, such as Leu-Tyr or Phe-Met. 
Interestingly the F-Z pair stabilizes the helical structure less than the F-F pair. Granted that Z is 
more hydrophobic than F, the results indicate that the F-F interaction has a significant polar-π 
component. Molecular modeling suggested that the F-F pair adopts either offset stacked or edge-
face geometry. However, since there were no structural data available, it was difficult to dissect 
the polar interaction as an energetic component from the overall stabilization effect. 
On the other hand, fluorination of the 
aromatic clusters in a globular protein with a well 
defined tertiary structure resulted in unpredictable 
effects to the global stability. Specifically, 
Gellman et al. investigated the effect of 
phenylalanine (F) to perfluorophenylalanine (Z) 
mutations on the stability of a 35-residue protein 
called chicken villin headpiece subdomain 
(HP35).
139
 There are three phenylalanines in the 
hydrophobic core of this protein (F6, F10 and F17, Figure 3-6). Single, double, or triple F to Z 
mutations were introduced at these three positions. Among all the seven mutants, only F10Z 
stabilized the protein structure compared to the wild type (the difference of the folding free 
energy between F10Z and WT, ΔΔGf=-0.6 kcal/mol), and all other mutants either destabilized the 
protein structure or had no influence on the peptide stability. This destabilization effect of 
fluorination agrees well with Tsuzuki’s prediction: fluorination on the aromatic side chains that 
Figure 3-6. The crystal structure of HP35 with 
three phenylalanines in the hydrophobic core 
region. The cyan colored labeled hydrogens are 
engaged in edge-face interactions 
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are engaged in edge-face interactions may reduce the protein stability. However, the energetic 
contributions from the hydrophobic effect and quadrupole interactions remain to be elucidated. 
In order to fully understand the effect of fluorinated aromatic amino acids to protein stability, 
it is essential to dissect the energetic components from the overall stability changes, including the 
hydrophobic effect and the quadrupole interaction. A model system that meets the following 
requirements is necessary for the investigation: 
a. The geometries of the interacting side chains are well defined. 
b. The interacting side chains are located in a hydrophobic environment in order to 
minimize the solvent effects. 
In addition to these requirements for the model system, fluorinated aromatic amino acids with 
varied degrees and patterns of fluorination are also necessary for systematic investigations. In the 
following sections, I will introduce two peptide model systems (HP35 and α2D) that I used to 
study edge-face interaction and face-face stacked interaction between aromatic and fluoro-
aromatic side chains, respectively. From these studies, we investigated the two typical modes of 
aromatic interactions in protein system, and the dissected energetic components in these 
interactions. The results of this study provided a fundamental understanding of aromatic 
interactions in protein systems, and guidelines for protein engineering with fluorinated aromatics 
for stabilizing protein structure or directing specific protein-protein interactions. 
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3.2 Probing edge-face aromatic interactions with tetrafluorinated phenyalanine 
The model system I used to study edge-face interactions in a protein system is the chicken 
villin headpiece (HP35), which has been widely used in studies of protein folding
139
 (Figure 3-6). 
As previously discussed, the HP35 structure features three interacting phenylalanines in the 
hydrophobic core region: the para-hydrogen of F6 packs against the phenyl ring of F17, while the 
ortho hydrogen of F10 packs against the π cloud of F6 (Figure 3-6).  Mutating one or more 
phenylalanines to perfluorinated phenylalanines can destabilize its folded structure. This 
destabilization effect is hypothesized to be the result of eliminating the favored edge-face 
interactions by replacing the involved hydrogens with fluorines. We propose that instead of using 
perfluorophenylalanine, tetrafluorophenylalanine should be able to offer enhanced 
hydrophobicity (comparing to the wild type), yet still retain the key aromatic hydrogens needed to 
engage in edge-face interactions, thus affording a stabilized protein fold. 
To test the hypothesis, two phenylalanine analogues were synthesized: 2,3,4,5-tetrafluoro-L-
phenylalanine (Zo) and 2,3,5,6-tetrafluoro-L-phenylalanine (Zp, Figure 3-4). These two unnatural 
amino acids were incorporated into HP35, and their energetic perturbations to the peptide 
structure stability were examined in comparison to that of pentafluoro-L-phenylalanine (Z).  
 
3.2.1 Synthesis of tetrafluorinated phenylalanines and HP35 variants 
The synthetic route for the tetrafluorinated phenylalanines is shown in Scheme 3-1. 
Stereoselective benzylation of Seebach’s (S)-Boc-BMI (BMI=2-tert-butyl-3-methyl-4-
imidazolidinone) is followed by hydrolysis to generate the free amino acid analogues (Scheme 3-
1). The amino acid analogues were then transformed into the Fmoc-protected form, which were 
readily incorporated into HP35 through solid phase peptide synthesis (SPPS).  
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Scheme 3-1. Synthesis of tetrafluorinated phenyalalnine (Zo) 
HP35 variants F6Zp and F10Zo were synthesized through standard Fmoc-SPPS procedure. As 
control sequences, we also prepared HP35 variants F6Z and F10Z. The peptide variants were 
purified though prep-scale HPLC and size exclusion chromatography. The purity and MS were 
characterized by LC-MS (See Experimental Procedures). 
 
3.2.2 Structural characterization of HP35 variants 
Structural characterization of the HP35 variants were carried out with circular dichroism (CD) 
and NMR spectroscopic analyses. The CD  spectra of all HP35 mutants overlapped with the WT 
and displayed characteristic ellipticity minima at 208 and 222 nm for α-helical structures (Figure 
3-7), indicating all the peptide variants were well folded.  
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Figure 3-7. CD spectra of HP35 variants. 
The structures of HP35 mutants are further examined by 1D 
1
H-NMR spectroscopy. (Figure 
3-8) Well-dispersed resonances and nearly identical patterns were observed for all HP35 variants, 
indicating that the fluorinated mutants all adopt stable and native-like structures. More 
specifically, HP35 WT displays two upfield shifted resonances (-0.51 and 0.10 ppm), which are 
assigned to be the H
γ
 of Val9 and H
δ
 of Leu20, respectively. Their packing against aromatic side 
chains is responsible for the upfield shift. These characteristic resonances are evidently preserved 
in the HP35 mutants, strongly suggesting no major structural perturbations by the fluorinated 
amino acids. 
 
Figure 3-8. 1D 
1
HNMR spectra for HP35 variants in 10% D2O, pH 5.5 
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3.2.3 Thermodynamic characterization of thermodynamic properties of HP35 variants 
The thermal stabilities of HP35 variants were investigated through thermal melting 
experiments monitored using circular dichroism (CD). The peptides were slowly heated up to 98 
◦
C from 2 
◦
C and cooled back down in a temperature step of 2 degrees between each measurement, 
and at each step the solution was equilibrated for 90 sec and measured the average signal in 15 
sec. The peptide structure change was indicated by the ellipticity at 222 nm. For all the HP35 
variants, the (un)folding is completely reversible (Experimental Procedures), and the melting 
curves were fitted to a two-state model to give the melting temperature (Tm) values (Table 3-2).  
Table 3-2. Thermodynamic parameters of HP35 variants 
 
The folding free energies (ΔGf) were obtained from guanidinium chloride denaturation 
experiments (Figure 3-9). The peptide conformation was monitored as a function of guanidinium 
chloride concentration using CD spectroscopy. The linear relationship between the guanidinium 
chloride concentration and the equilibrium of folded and unfolded peptide was used for 
calculating the folding free energies (ΔGf) which were summarized in Table 3-2.  
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Figure 3-9. Guanidinium chloride (GdmCl) denaturation curves (fitted) for HP35 variants. 
As expected, a F to Zo mutation at residue 10 enhances HP35 stability by a large margin; 
F10Zo is more stable than the WT by 14 
◦
C in Tm and -1.4 kcal/mol in ΔGf. Furthermore, 
consistent with our hypothesis, the tetrafluorophenylalanine mutant F10Zo exhibits higher 
stability than the pentafluorophenylalanine mutant F10Z (12 
◦
C in Tm and-1.1 kcal/mol in ΔGf). 
Given that there is only one atom difference between Zo and Z (hydrogen vs fluorine), and Z is 
more hydrophobic than Zo, we attribute the superior stability of F10Zo to the edge-face interaction, 
which is retained in F10Zo and eliminated in F10Z. Another tetrafluorinated phenylalanine 
mutant F10Zp is less stable than F10Zo by -1.5 kcal/mol. Since the aromatic hydrogen on Zo is not 
engaged in the edge-face interaction, the result strongly argues that the enhanced stability of 
F10Zo comes from the edge-face interaction enabled by Zo. 
For the mutations on the F6 position, the mutant F6Zp is also more stable than the mutant F6Z 
(11
○
C in Tm and -0.3 kcal/mol in ΔGf), indicating the edge-face interaction is also a very 
important energetic factor here. However, both F6 mutants are destabilized compared to the wild 
type. As discussed before, this can be explained by the edge-face interactions. Unlike F10, F6 is 
engaged in two edge-face interactions: as a π-cloud donor in the F10-F6 pair and as a hydrogen 
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donor in the F6-F17 pair. The F6Zp mutation enhances the partial positive charge on the 
remaining hydrogen, thus improving the edge-face interaction between F6 and F17. In contrast, 
fluorination on F6 also decreases the electron density of the π-cloud, thus weakening the 
interaction between F10 and F17.  
It is also interesting to note that the contribution of this enhanced edge-face interaction to the 
folding energy is about -1.1 kcal/mol between F10Z and F10Zo, but only about -0.3 kcal/mol 
between F6Z and F6Zp. With a closer examination of the HP35 structure, we found that the F6 
position is partially exposed to solvent, but the F10 position is completely buried in the 
hydrophobic core. Solvent exposure would be expected to weaken the edge-face interaction given 
its electrostatic nature.  
 
3.2.4 Summary of edge-face interactions 
In summary, we have investigated edge-face interactions of aromatic side chains in a model 
protein HP 35. We have synthesized two tetrafluorophenylalanines which, upon incorporation 
into protein structures, have shown to contribute more favorably to protein stability than 
pentafluoro-phenylalanines. Our data strongly suggest the enhanced stability is due to the 
retention and possibly strengthening of these edge-face interactions by highly, but not fully, 
fluorinated aromatic molecules.   
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3.3 Probing quadrupole interactions in face-face stacked aromatic pairs 
A highly fluorinated aromatic system affords electron-deficient π-clouds. Driven by 
electrostatic interactions, it tends to associate in a face-face stacked fashion with natural aromatic 
systems, which contain electron-rich π-clouds. The phenyl and perfluorophenyl pair has been 
previously incorporated into small molecules and polymers to afford molecular assembly.
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However, the attempts to install this interaction into protein systems have not been successful.
80, 
140
 We hypothesized that the major reason for failure is that this interaction requires both a 
nonpolar environment and a low entropy penalty. 
 
3.3.1 Selecting α2D as model system to study 
face-face stacked aromatic interaction 
Here, we investigated the face-face stacked 
interaction between aromatic side chains in a model 
peptide α2D (Figure 3-10).
141
 The de novo designed 
peptide α2D folds as a helical homodimer. The four 
helix-bundle of the peptide dimer displays a 
hydrophobic core, where two pairs of face-face 
stacked phenylalanines are located. The side chain 
of F10 from one monomer stacks against the side 
chain of F29 from the other monomer. By 
analyzing the NMR structure of wild type α2D, we 
found that the two phenyl pairs adopt a perfect 
parallel stacked geometry, with the centroid-to-centroid distance of 3.17±0.14Å and dihedral 
angles close to zero (12±5
◦
). Molecular modeling has indicated that the hydrophobic core region 
Figure 3-10. Representation of the dimeric 
structure of α2D (PDB: 1QP6). The front helix of 
the monomer in blue is omitted to make the 
aromatic cluster visible. Right: space-filling 
models of stacked side chains of F and Z, with 
the electrostatic potential mapped on their 
surface (blue: positive, red: negative). 
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is densely packed. (Experimental Procedures, Figure 3-26) Therefore the rotation of any single 
phenylalanine side chain should be prohibited by the steric bulk from neighboring side chains.  
Besides the preorganized face-face stacked geometry, another reason to select this peptide as 
the model system is that this peptide dimer folds with a reversible, two-state mechanism 
(unfolded monomer and folded dimer). Therefore, we can analyze the peptide stability by 
monitoring the association/dissociation of the dimer. Furthermore, the dimerization process 
allows us not only to investigate the stabilization effect of this phenyl-perfluorophenyl interaction, 
but also to examine whether this interaction can direct specific protein-protein association. 
 
3.3.2 Synthesis and structure characterizations of α2D variants 
Through standard Fmoc-SPPS, we synthesized the wild-type (WT) α2D, two single-mutants 
(F10Z), (F29Z), and the double-mutant (F10, 29Z). For clarity, the homodimers are referred to as 
(WT, WT), (F10Z, F10Z), (F29Z, F29Z) and (F10,29Z, F10,29Z), respectively. The CD analysis 
showed that all the α2D peptide variants, fold into stable helical structures, exhibiting the 
characteristic double-minima signature (208 and 222 nm) for α-helices. Gel-filtration analysis 
confirmed that the fluorinated mutants were well folded dimers: all the mutants were eluted as a 
single peak with an essentially identical retention time as the WT, falling between the two protein 
controls (with molecular weights of 4.5 KDa and 13.7 KDa, respectively) (Figure 3-11). Given 
the molecular weight of about 4.3 KDa for the α2D monomer, the gel-filtration result strongly 
indicates that the mutants retained the dimeric structure of the WT α2D.  
88 
 
 
Figure 3-11. Gel filtration traces of α2D variants. All peptides (WT and mutants) showed a single peak at 
the same retention time, falling between the two control protein peaks. 
 
3.3.3 Investigation of thermodynamic properties of α2D variants 
Attempts at quantifying the folding free 
energies (ΔGf) of the α2D variants with 
guanidinium chloride (GdmCl) denaturation 
failed. These proteins were highly sensitive to 
chemical denaturants; no pre-transition 
baseline was observed, even in presence of 
2M TMAO (trimethylamine N-oxide), a well-
established stabilizing osmolyte 
(Experimental Procedures).
142
 Alternatively, 
we decided to analyze the thermal melting 
data at varied protein concentrations, and calculated thermodynamic parameters from the van’t 
Figure 3-12. van’t Hoff plot for the α2D variants. 
The plots of ln(Kf) against 1/Tm fit a linear 
relationship well.  
89 
 
Hoff equation. Because of the dimeric fold, a more concentrated sample should yield a higher 
melting temperature. For each α2D variant, thermal melting curves at five different concentrations 
were recorded with the CD spectrometer monitored at 222nm. The van’t Hoff analyses were 
carried out by plotting ln(Kf) against 1/Tm (Figure 3-12). Kf is the association constant for α2D 
dimerization at the corresponding Tm, which can be easily calculated from the total protein 
monomer concentration. The plots of ln(Kf) against 1/Tm fit a linear relationship well, indicating 
that the heat capacity change (ΔCp) of α2D unfolding is rather minor (Figure 3-12). The folding 
enthalpy (ΔHf) values were calculated based on the slopes of the linear fits of the van’t Hoff plots, 
which further yielded the folding free energies of the α2D variants as showed in Table 3-3 (see 
Experimental Procedures for details). 
Table 3-3. Thermodynamic parameters of the α2D variants.  
 
To estimate the energetic contribution of F–Z quadrupole stacking, we devised a double-
mutant cycle (Figure 3-13) that consists of the four α2D peptide variants. Double-mutant cycles 
have been commonly used to analyze specific pairwise interactions.
143
 In the double-mutant cycle 
diagram, comparing the wild type homodimer (WT, WT) with the single mutant (F29Z, F29Z), 
we conclude that F to Z mutation at position 29 stabilizes the peptide by 5.0 kcal/mol. The 
stabilization effect can be dissected into two energetic components, the contribution of the 
quadrupole interaction (ΔGquad) and that of other factors (ΔGother) such as hydrophobicity, steric 
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effects, and possibly other weak interactions involving the C-F bonds (see Experimental 
Procedures for details).  
 
Figure 3-13. The double mutant cycle of α2D variants. The folding free energy (kcal/mol) is displayed 
underneath the corresponding peptide. The energetic components can be dissected by analyzing the double-
mutant cycles. 
Comparing the single mutant (F10Z, F10Z) vs. the double mutant (F10, 29Z, F10, 29Z), the 
F-to-Z mutation at residue 29 eliminates the favorable quadrupole interaction (-ΔGquad) and 
introduces the same energetic perturbation as (F29Z, F29Z) does by other factors (ΔGother). The 
double-mutant (F10,29Z, F10,29Z) is more stable than (F10Z, F10Z) by -0.8±0.5 kcal/mol, 
corresponding to the value of (-ΔGquad+ΔGother). Based on these considerations, the strength of 
quadrupole interaction between a stacked F-Z pair (ΔGquad) can be estimated based on the 
thermodynamic stabilities of the protein variants involved in the double-mutant cycle. The 
estimation of the total energetic gain due to quadrupole stacking is about of -2.1±0.6 kcal/mol. 
Because the α2D dimer structure consists of two F-Z pairs, each F-Z pair contributes -1.0±0.3 
kcal/mol. It is worth noting that a repulsive interaction may exist between a pair of stacking 
aromatic rings with quadrupole moments of the same sign. Therefore, the estimated value of 
ΔGquad herein reflects the combined effect of eliminating the repulsive quadrupole interaction 
(between the F-F or Z-Z pairs) and introducing the attractive interaction of the F-Z pair. In other 
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words, the ΔGquad value should be considered as the upper limit of the quadrupole attraction 
between F and Z. 
This estimated value for the quadrupole interaction in a stacked F-Z pair agrees well with 
previously reported data generated from small molecule model systems. For example, Siegel et al. 
reported about -1.0 kcal/mol for the polar-π interaction between electron-rich and electron-poor 
aromatic rings based on their study of rotational barriers of 1,8-diarylnaphthalenes.
144
 A similar 
value was also reported by Santa et al. by measuring benzene-perfluorobenzene association using 
NMR spectroscopy.
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3.3.4  Heterodimerization directed by F-Z quadrupole interactions 
We were curious whether the mixture of wild type homodimer (WT, WT) and the double 
mutant homodimer (F10,29Z, F10,29Z) would generate a heterodimer or remain as separate 
homodimers. Since the energetic contribution of an F-Z stacked pair to the dimer stability could 
be dissected into two components, the non-specific energetic factor ΔGother should not be affected 
too much by heterodimerization due to the similar environment in the hydrophobic core, but the 
quadrupole interaction between F and Z should favor the heterodimer. We hypothesized that 
mixing of the homodimers should give the heterodimer (WT, F10,29Z), in which side chains of F 
and Z are engaged in face-face stacked quadrupole interactions.  
 
1) Thermal melting experiments. 
The thermal melting curves of both homodimers (WT, WT) and (F10,29Z, F10,29Z) display 
cooperative two-state transitions. As we discussed in the previous context, the fluorinated peptide 
exhibits greatly improved thermal stability, with a melting temperature of 79.8 
◦
C in contrast to 
29.8 
◦C for the WT α2D at the same concentration (Figure 3-14). Similar to the two homodimers, 
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the mixture of (WT, WT) and (F10,29Z, F10,29Z) at equal concentrations displays an apparent 
single transition instead of a two-stage profile expected for the sequential melting of (WT, WT) 
and (F10,29Z, F10,29Z). This observation is evidence of the heterodimer formation (WT, 
F10,29Z). 
 
Figure 3-14. Thermal melting curves (fitted) of α2D WT and F10,29Z homodimer and the mixture 
 
2) FRET (fluorescence resonance energy transfer) assay 
We further examined the heterodimer formation through a FRET assay (Figure 3-15). Two 
fluorophores, nitrobenzofurazan (NBD) and tetramethylrhodamine (TAMRA), were conjugated 
onto the solvent exposed N-terminus of α2D WT and F10,29Z mutant respectively with a β-
alanine as a linker. The fluorophore-labeled peptides fold into dimeric helical structures and 
display Tm values similar to the corresponding unlabeled peptides (Experimental Procedures), 
which proves that the fluorescent labels introduce little perturbation to the dimeric structure and 
stability.  
The excitation wavelength of TAMRA group (540 nm) is very close to the emission 
wavelength of NBD. While excited at 460 nm, close to the absorption maximum of NBD, the 
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NBD-labeled homodimer (WT, WT) displays a strong emission peaked at 540 nm, whilst the 
TAMRA-labeled homodimer (F10,29Z, F10,29Z) yields a weak emission at 587 nm (Figure 3-15 
b). However, under the same excitation wavelength, the mixture of the two homodimers at equal 
concentrations displayed the complete disappearance of the NBD fluorescence and a three-fold 
increase in TAMRA emission. Adding the NBD-labeled (WT, WT) into the solution of TAMRA 
alone resulted in no change in the fluorescence emission. Importantly, the gelfiltration analysis 
revealed that the mixture eluted as a single peak with an identical retention time as the 
homodimers (Experimental Procedures). Therefore, we attribute the fluorescence energy transfer 
to the heterodimer formation that brings NBD and TAMRA into proximity. 
 
Figure 3-15. a) The FRET assay designed to examine the heterodimer formation between the WT α2D and 
fluorinated variants. The WT and F10,29Z peptides are labeled with NBD (yellow circles) and TAMRA 
(red squares), respectively. b) The fluorescence emission data with excitation at 460 nm.  
 
3) Evidences of heterodimerization from 
1
H NMR and 
19
F NMR 
The heterodimerization was further probed by NMR spectroscopy. In the 
1
H NMR spectra, 
the aromatic and amide regions of the two homodimers and their mixture are shown in Figure 3-
16A. Since the double mutant is more stable than the wild type, it is expected that the (F10,29Z, 
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F10,29Z) will exhibit more highly dispersed signals than (WT, WT) as a consequence of a better 
defined folded structure. The N-H signals of Trp residues were easily identified owing to their 
downfield chemical shifts. The double mutant homodimer is slightly downfield shifted (10.81 
ppm) compared to the WT homodimer (9.85 ppm). Both Trp N-H signals are presented as a 
single peak, suggesting the homogeneous environment of this hydrogen in the homodimers. 
Mixing of (WT, WT) and (F10,29Z, F10,29Z) results in the complete disappearance of the signal 
at 9.85 ppm. Instead, the peaks appeared at 10.85 and 10.90 ppm, which suggests that the two 
tryptophans are placed in different local environments, as expected for the heterodimer (WT, 
F10,29Z). 
 
Figure 3-16. A) 
1
H and B) 
19F NMR spectra of the α2D homo/heterodimers. Mixing of the homodimers 
results in the downfield shift of the Trp N-H signal and the splitting of the ortho and meta fluorine signals. 
These data strongly support the formation of the (WT, F10,29Z) heterodimer. 
 
19
F-NMR provided additional evidence for the heterodimer formation (Figure 3-16B). 
(F10,29Z, F10,29Z) exhibits four peaks with an integration ratio of 4:1:1:4. The peaks with the 
integration of 1 correspond to the para fluorine atoms of Z10 and Z29. The fluorine atoms at the 
ortho and meta positions each appear as a single peak with an integration of 4. Upon mixing with 
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(WT, WT), the ortho-F and meta-F peaks each split into two with equal integration, indicating 
that the two Z side chains are placed into different local environments from those of (F10,29Z,  
F10,29Z).  
Collectively, these results show that the favorable F-Z quadrupole interaction drives the 
heterodimer formation. 
 
3.3.5 Summary for the study of F-Z stacked interactions in protein system 
We have used the peptide model system α2D to examine the significance of the F-Z stacking 
interactions in protein folding and protein-protein association. Our data shows that, with proper 
structured context, an F-Z stacked pair can be installed into protein systems to stabilize structures. 
The thermodynamic study showed that the quadrupole interaction in an F-Z pair can enhance the 
protein stability by as much as 1.0 kcal/mol. We further investigated the possibility of utilizing 
the F-Z pair for directing specific protein-protein association, which could be potentially used as 
a novel non-covalent interaction in protein engineering. 
 
3.4 Conclusion 
In summary, we have investigated the consequence of fluorinating aromatic residues in two 
peptide model systems: HP35 and α2D. The aromatic side chains adopt the edge-face geometry in 
HP35 and the face-face stacked geometry in α2D. Introducing fluorinated aromatic residues into 
these two model systems allowed us to investigate the perturbation of fluorinated aromatic 
residues to protein stabilities and isolate the energetic components of polar-π interactions. It has 
been shown in our experiments that polar-π interactions can be critical for protein stability. The 
effect of fluorinating an aromatic residue in a protein depends on the polar- π interactions that 
aromatic residue is involved in. By carefully analyzing the local environment of the aromatic 
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residue of interest, we can estimate the energetic perturbation of fluorination, according to the 
thermodynamic parameters we obtained from the model systems. This research provides a 
guideline for protein engineering with fluorinated aromatic amino acids. 
We also discovered the potential of aromatic-fluorinated aromatic interactions in directing 
specific protein-protein association. Specific protein-protein association serves as the basis of 
numerous biological processes, including the regulation of gene expression, signal transduction, 
and the assembly of molecular machinery. The aromatic-fluorinated aromatic interactions are 
expected to be most effective in a hydrophobic environment such as the lipid bilayer. It follows 
that, fluorinated aromatic residues could be used for targeting the interface of interacting 
membrane proteins. For example, the V659E mutation on HER2 transmembrane domain is 
oncogenic due to the excessive dimerization it causes.
128
 The structure of the α-helical dimer 
affords two phenylalanines packing against each other at the interface. A peptide could be 
engineered to mimick HER2 transmembrane domain, but with fluorinated phenylalanine installed 
at the protein-protein interface. This design could potentially inhibit the native protein 
dimerization process due to the favored aromatic-fluoroaromatic interaction (Figure 3-17).  
 
Figure 3-17. A) The NMR structure of HER2 transmembrane domain (PDB: 2JWA). Two phenylalanine 
side chains are packing against each other at the interface. B) Proposed strategy of engineering peptide 
probes to disturb transmembrane protein-protein association. 
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Experimental Procedures 
PART I. Strengthen edge-face aromatic interactions with tetra-fluorinated phenyalanine 
I. General methods. 
(S)-(-)-1-Boc-2-tert-butyl-3-methyl-4-imidazolidinone ((S)-Boc-BMI) was purchased from 
Aldrich. 2,3,4,5-tetrafluorobenzyl bromide and 2,3,5,6-tetrafluorobenzyl bromide were purchased 
from Matrix Scientific (Columbia, SC). Fmoc-OSu and HBTU were purchased from 
Novabiochem (San Diego, CA). The tetrafluoro-L- phenylalanine derivatives were synthesized 
following the procedures described below. All other Fmoc-protected amino acids were purchased 
from Advanced Chemtech (Louisville, KY). Peptide synthesis was carried out on a Tribute 
peptide synthesizer (Protein Technologies, Tucson, AZ). 
1
HNMR and 
13
C-NMR data were 
collected on a Varian Gemini 400 MHz NMR spectrometer. 
1
H-NMR data for peptides were 
taken on a Varian INOVA 500 MHz NMR spectrometer. HR-MS data were generated by the 
Boston College Mass Spectrometry Center. Circular dichroism measurements were performed on 
an AVIV CD spectrometer (Aviv Biomedical Inc. Lakewood, NJ). The protein concentration of 
all samples used in this study was determined by measuring their absorption at 280 nm on a 
Lambda 25 UV-Vis spectrometer (PerkinElmer, Waltham, MA). The extinction coefficient ε (280 
nm) was calculated using ExPASy ProtParam Tool (http://ca.expasy.org/tools/protparam.html) to 
be 5500 M
-1
 cm
-1
. The van der Waals volumes of toluene (and its fluorinated derivatives) were 
calculated using Spartan software (Wavefunction, Inc.) as an estimate for the side chain of 
phenylalanine (and the corresponding derivatives). The solvent accessible surface area (SASA) is 
calculated using the webtool GETAREA (http://curie.utmb.edu/getarea.html).
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II. Synthesis and characterization of Fmoc-tetrafluorinated phenylalanine derivatives. 
Scheme 3-1. Synthesis of tetrafluorinated phenylalanine. 
a : 2,3,4,5-flourinated benzyl side chain 
b : 2,3,5,6-flourinated benzyl side chain 
 
(2S,5S)-2-t-butyl-1-t-butyloxiycarbonyl-3-methyl-2,3,4,5-tetrafluorobenzyl-4-
imidazolidinone (3-1a) 
A solution of diisopropylamine (5.85 mmol) in dry THF (3.0 mL) was chilled to -50 °C under 
argon protection, to which n-butyllithium (2.5 N solution in hexane, 2.34 mL 5.85 mmol) was 
added to give a fresh solution of LDA. After 15 min of stirring, DMPU (1.40 mL 11.7 mmol) and 
(S)-Boc-BMI (1.01 g 3.94 mmol) in dry THF (3 mL) were added, and the mixture was kept 
stirring for an additional 30 min at -50 °C. Then 2,3,4,5-tetrafluorobenzyl bromide (1.9 g, 7.8 
mmol) in dry THF (1.5 mL) was added via syringe.  
The reaction mixture was kept stirring at -50 °C for 3 hours before it was quenched with 
saturated NH4Cl solution (2.0 mL). The product was extracted with diethyl ether (4×10 mL). The 
organic layer was combined, washed with 2 N citric acid, sat.aq. NaHCO3 and water, and then 
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dried with Na2SO4. The solvent was evaporated under vacuum and the crude material was 
purified by flash column chromatography (ethyl acetate/hexane, 1:5) to give the desired S-isomer 
1a as a white solid (1.17 g, 70%). No R-isomer was detected in our synthesis. 
1
H: CDCl3, 400 
MHz δ= 6.81-6.74 (m, 1H), 4.85 (s, 1H), 4.31 (s, 1H), 3.58 (s, 1H), 3.39-3.35 (m, 1H), 2.95 (s, 
3H), 1.45 (s, 9H), 0.97 (s, 9H). 13C: CDCl3, 400 MHz, δ=171.1, 152.5, 147.7, 145.2, 141.9, 
140.5, 139.4, 137.9, 120.5, 112.1, 111.9, 81.8, 81.2, 58.8, 41.2, 32.1, 28.2, 26.7. HRMS calcd for 
C20H27F4N2O3 [M
+
] 419.1958, found 419.1954. 
 
(S)-2-amino-3-(2,3,4,5-tetrafluorophenyl)-propionic N’-methylamide (3-2a) 
The compound 1a (1.17 g, 2.79 mmol) was dissolved in methanol (20 mL) and mixed with 1 
N HCl solution (20 mL) at room temperature. The reaction mixture was kept refluxing overnight. 
Then methanol was removed under vacuum and the pH of the remaining aqueous phase was 
adjusted to 9-10 with 2 N KOH solution. The product was extracted out of the aqueous solution 
with CH2Cl2 (6×20 mL). The combined organic fractions were dried with Na2SO4 and the solvent 
was evaporated under vacuum. After column purification (CH2Cl2/MeOH, 9:1, 2% DIPEA), the 
product was obtained as a white solid (532 mg, 76%). 
1
H: CDCl3, 400 MHz, δ=6.94-6.87 (m, 1H), 
3.62-3.49 (m, 1H), 3.27-3.23 (m, 1H), 2.89-2.82 (m, 1H), 2.81 (s, 3H), 1.41 (s, 2H). 13C: CDCl3, 
400 MHz, δ=173.8, 148.1, 147.4, 145.7, 145.1, 142.0, 140.6, 139.4, 138.0, 121.6, 112.4, 112.2, 
55.5, 33.9, 26.0. HRMS calcd for C20H27F4N2O3 [M
+
] 251.0808, found 251.0813. 
 
(S)-2-amino-3-(2,3,4,5-tetrafluorophenyl)-propionic acid (3-3a)  
The N’-methylamide 2a (94 mg, 0.37 mmol) was dissolved in 2 N KOH (20 mL) at room 
temperature, and the solution was then refluxed for 2.5 h. After adjusting the pH of the solution to 
5-6 with 2 N HCl at room temperature, water was removed under vacuum. The residue was 
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suspended in anhydrous ethanol, and the insoluble salt was removed by centrifugation. The 
supernatant was collected and the solvent was evaporated under vacuum and gave the product as 
a white solid (85.5 mg, 96%). 
1
H: CD3OD, 400 MHz, δ=7.09-7.06 (m, 1H), 4.11 (m, 1H), 3.30-
3.25 (m, 1H), 3.12-3.06 (m, 1H). 
13
C: CD3OD, 400 MHz, δ=170.9, 163.2, 162.8, 149.6, 149.3, 
147.2, 146.7, 143.4, 142.6, 140.9, 140.127, 120.4, 114.3, 114.1, 54.2, 30.5. HRMS calcd for 
C20H27F4N2O3 [M
+
] 238.0491, found 238.0500. 
 
N-(9-Fluorenylmethoxycarbonyl)-L-2,3,4,5-tetrafluorophenylalanine (3-4a) 
The amino acid 3a (174 mg, 0.73 mmol) was suspended in 9% sodium carbonate solution (2 
mL) at 0 °C in an ice bath, and a solution of Fmoc-OSu (296.2 mg, 0.88 mmol) in DMF (1.5 mL) 
was added. The reaction mixture was kept stirring for 3 h at room temperature. Then 25 mL water 
was added and the diluted mixture was extracted with diethyl ether (2 mL) and ethyl acetate (2×2 
mL). The aqueous phase was then acidified to pH 2 with concentrated HCl solution, and extracted 
with ethyl acetate (6×5 mL). The organic phase was combined, washed with sat. aq. NaCl 
solution (3×3 mL), water (2×3 mL), and dried with Na2SO4. Evaporation of the solvent, and 
purification by column chromatography (ethyl acetate/hexane, 1:1, 2% acetic acid) gave the 
product 4a as a white solid (250mg, 74%). 
1
H: CD3OD, 400 MHz, δ=7.70-7.67 (m, 2H), 7.56-
7.49 (m, 2H), 7.30-7.26 (m, 2H), 7.23-7.17 (m, 2H), 7.00-6.94 (m, 1H), 4.82-4.34 (m, 1H), 4.33-
4.15 (m, 2H), 4.11-4.05 (m, 1H), 3.29-3.22 (m, 1H), 2.90-2.84 (m, 1H). 
13
C: CD3OD, 400 MHz, 
δ= 174.2, 158.4, 149.2, 148.8, 146.9, 146.4, 145.4, 145.3, 145.2, 143.1, 142.6, 141.8, 140.5, 
139.3, 128.8, 128.2, 126.2, 121.0, 114.1, 113.9, 68.1, 67.9, 55.3, 37.9, 35.3, 31.8. HRMS calcd 
for C20H27F4N2O3 [M
+
] 460.1172, found 460.1165. 
(2S,5S)-2-t-butyl-1-t-butyloxiycarbonyl-3-methyl-2,3,5,6-tetrafluorobenzyl-4-
imidazolidinone (3-1b) 
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0.8 mL of diisopropylamine (5.85 mmol) dissolved in dry THF (3.0 mL) was chilled to -
50 °C under Argon protection, to which n-butyllithium (2.5 N solution in hexane, 2.34 mL 5.85 
mmol) was added to give a fresh solution of LDA. After 15 min of stirring, DMPU (1.40 mL 11.7 
mmol) and (S)-Boc-BMI (1.01 g, 3.94 mmol) in dry THF (3 mL) were added, and the mixture 
was kept stirring for additional 30 min at -50 °C. Then 2,3,5,6-tetrafluorobenzyl bromide (1.9 g, 
7.8 mmol) in dry THF (1.5 mL) was added via syringe. The reaction mixture was kept stirring at -
50 °C for 3 hours before it was quenched with saturated NH4Cl solution (2.0 mL). The product 
was extracted with diethyl ether (4×10 mL). The organic layer was combined, washed with 2 N 
citric acid, sat.aq. NaHCO3 and water, and then dried with Na2SO4. The solvent was evaporated 
under vacuum and the crude material was purified by flash column chromatography (ethyl 
acetate/hexane, 1:5) to give the desired product 1b as a white solid (1.10, 66%). The S-
configuration the newly generated chiral center was confirmed by the 2D-NOESY data (Fig. S2-
1). No detectable amount of the R-isomer was observed. 
1
H: CDCl3, 400 MHz, δ=6.99-6.91 (m, 
1H), 5.02 (s, 1H), 4.29 (s, 1H), 3.95-3.91 (m, 1H), 2.98 (s, 3H), 1.50 (s, 9H), 0.98 (s, 9H). 
13
C: 
CDCl3, 400 MHz, δ=170,8, 152.9, 147.0, 146.5, 144.5, 144.3, 117.1, 104.4, 104.2, 104.0, 81.6, 
80.9, 56.9, 41.1, 32.0, 28.3, 26.6. HRMS calcd for C20H27F4N2O3 [M
+
] 419.1958, found 419.1945. 
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Figure 3-18. 2D-NOESY data illustrating the stereochemistry of the synthesized amino acid. The 
assignment of proton resonances was accomplished with the 2D-COSY data. The presence of NOE 
coupling between Hd and Hb indicates the S-configuration of the newly generated chiral center, which in 
turn yields the desired L-amino acid. 
 
(S)-2-amino-3-(2,3,5,6-tetrafluorophenyl)-propionic N’-methylamide (3-2b) 
The compound 1b (950 mg, 2.26 mmol) was dissolved in methanol (20 mL) and mixed with 
1 N HCl solution (20 mL) at room temperature. The reaction mixture was kept refluxing 
overnight. Then methanol was removed under vacuum and the pH of the remaining aqueous 
phase was adjusted to 9-10 with 2 N KOH solution. The product was extracted out of the aqueous 
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solution with CH2Cl2 (6×20 mL). The combined organic fractions were dried with Na2SO4 and 
the solvent was evaporated under vacuum. After column purification (CH2Cl2/MeOH, 9:1, 2% 
DIPA), the product was obtained as a white solid (377 mg, 67%). 
1
H: CDCl3, 400 MHz, δ=7.05-
6.97 (m, 1H), 3.63-3.60 (m, 1H), 3.41-3.36 (m, 1H), 2.92-2.86 (m, 1H), 2.84-2.82 (d, 3H, J=4.8 
Hz), 1.64 (s, 2H). 
13
C: CDCl3, 400 MHz, δ=173.9, 147.2, 147.0, 146.2, 144.6, 144.5, 144.4, 143,8, 
118.1, 117.9, 117.8, 104.7, 104.5, 104.3, 54.8, 50.3, 29.1, 26.0. HRMS calcd for C20H27F4N2O3 
[M
+
] 251.0808, found 251.0817. 
 
(S)-2-amino-3-(2,3,5,6-tetrafluorophenyl)-propionic acid (3-3b) 
The N’-methylamide 2b (341 mg, 1.36 mmol) was dissolved in 2 N KOH (20 mL) at room 
temperature, and the solution was then refluxed for 2.5 h. After adjusting the pH of the solution to 
5-6 with 2 N HCl at room temperature, water was removed under vacuum. The residue was 
suspended in anhydrous ethanol, and the insoluble salt was removed by centrifugation. The 
supernatant was collected and the solvent was evaporated under vacuum and gave the product as 
a white solid (280 mg, 86.6%). 
1
H: CD3OD, 400 MHz, δ=7.42-7.33 (m, 1H), 4.15 (t, 1H, J=7.2 
Hz), 3.56-3.27 (m, 2H). 
13
C: CD3OD, 400 MHz, δ=170.4, 148.6, 148.0, 146.2, 145.4, 116.0, 
115.8, 115.6, 107.5, 107.2, 107.0, 53.2, 25.3. HRMS calcd for C20H27F4N2O3 [M
+
] 238.0491, 
found 238.0490. 
 
N-(9-Fluorenylmethoxycarbonyl)-L-2,3,5,6-tetrafluorophenylalanine (3-4b) 
The amino acid 3b (280 mg, 1.18 mmol) was suspended in 9% sodium carbonate solution (2 
mL) at 0 °C in an ice bath, and a solution of Fmoc-OSu (205 mg, 0.61 mmol) in DMF (1.5 mL) 
was added. The reaction mixture was kept stirring for 2 h at room temperature. Then 20 mL water 
was added and the diluted mixture was extracted with diethyl ether (2 mL) and ethyl acetate (2×2 
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mL). The aqueous phase was then acidified to pH 2 with concentrated HCl solution, and extracted 
with ethyl acetate (6×5 mL). The organic phase was combined, washed with sat. aq. NaCl 
solution (3×3 mL), water (2×3 mL), and dried with Na2SO4. The solvent was evaporated and the 
crude product was purified by column chromatography (ethyl acetate/hexane, 1:1, 2% acetic acid) 
to give the product 4b as a white solid (427 mg, 79%). 
1
H: CD3OD, 400 MHz, δ=7.75-7.73 (d, 
2H), 7.58-7.56 (d, 2H), 7.36-7.32 (m, 2H), 7.27-7.25 (m, 3H), 4.48-4.44 (m, 1H), 4.26-4.15 (m, 
2H), 4.12-4.08 (m, 1H), 3.36-3.32 (m, 1H), 3.20-3.14 (m, 1H). 
13
C: CD3OD, 400 MHz, δ=173.8, 
158.4, 148.4, 147.8, 146.0, 145.4, 145.2, 142.6, 128.8, 128.3, 126.3, 121.0, 118.5, 106.3, 106.1, 
105.9, 68.4, 54.6, 26.8. HRMS calcd for C20H27F4N2O3 [M
+
] 460.1172, found 460.1173. 
 
III. Peptide synthesis and characterization 
HP35 variants were synthesized through Fmoc/tBu chemistry with the Fmoc-Phe-Wang resin 
(Novabiochem) as the solid support. The synthesis was carried out on 0.1 mmole scale. Five 
equivalents of the commercially available amino acids were used for the coupling reaction. The 
incorporation of the Zo and Zp was accomplished by using two equivalents of the Fmoc-protected 
amino acids and extended coupling time (2 hours). The peptides were cleaved off the resin and 
deprotected with reagent K (80% TFA, 5% H2O, 2.5% EDT, 5% Thioanisole and 7.5% Phenol). 
The crude products were purified by RP-HPLC (Waters Prep LC, Jupiter 10u C18 300A Column), 
followed by gel filtration (ÄKTA FPLC with Hiload
TM
 Superdex
TM
 30 prep grade Column). The 
purified peptides were directly subjected to spectroscopic and thermodynamic analysis. 
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IV. Circular dichroism. 
All samples for CD wavelength scan were prepared in buffer (20 mM Na•Pi, 150 mM NaCl, 
pH 7.0) with the protein concentration being 50 μM. Far-UV CD spectra of HP35 variants were 
recorded using an AVIV model 202SF CD spectrometer equipped with a temperature-controlled 
cell holder using a 2 mm path length quartz cell. CD spectra were recorded from 195 to 260 nm at 
2 
◦
C and data are shown in Figure 3-9. All HP35 variants display ellipticity minima at 222 nm and 
208 nm, characteristic of α-helical structures.  
 
V. NMR spectroscopy of HP35 variants. 
All protein samples for NMR spectroscopy were prepared in 20 mM sodium phosphate buffer, 
pH 5.5, H2O/D2O 9:1 (v/v) with the protein concentration being 1 mM. 1D 
1
HNMR spectra of all 
HP35 varaints were collected at 2 
◦
C on a Varian INOVA 500 MHz NMR spectrometer. Water 
suppression was accomplished by using the WATERGATE pulse sequences. NMR data were 
processed by using the software MestRe Nova (Mestrelab Research S. L., Spain), during which 
digital suppression of the residue solvent peak was applied. 
 
VI. Thermal and thermodynamic analysis of HP35 variants. 
Thermal denaturation experiments were monitored at 222 nm over a temperature range of 2-
102 
◦
C for F10Zo and 2-96 
◦
C for other HP35 variants. The ellipticity data were collected with 2 
◦
C step size and a 90 s equilibration time. Signals were averaged for 30 s. Reverse temperature 
scan (renaturation) was performed after reaching the highest temperature. For all HP35 variants, 
the renaturation curve overlays well with the denaturation curve (Figure 3-19A), indicating that 
the folding is reversible. All thermal melting curves exhibit sigmoidal transitions (Figure 3-19B), 
which fit well to a two-state model to yield the Tm values (Table 3-2). Melting curves were 
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recorded with both 10 μM and 50 μM protein concentration. Essentially identical Tm values were 
obtained from analyzing the melting data with different protein concentrations, suggesting the 
(un)folding is an unimolecular process, i.e. no dimer or higher aggregates are involved. 
 
Figure 3-19. Thermal denaturation results of HP35 variants. (A) Denaturation and renaturation curves of 
HP35 F10Zo, displays the complete reversibility of HP35 folding. (B). The melting curves of HP35 
variants that show apparent two-state transitions. 
 
Guanidinium chloride (Gdm•Cl) denaturation experiments were carried out at 2 ◦C on the 
circular dichroism spectrometer. Two 10 μM protein solutions were prepared: solution A is in the 
native folding buffer (20 mM Na•Pi, 150 mM NaCl, pH 7.0) and solution B is in the denaturing 
buffer (20 mM Na•Pi, 150 mM NaCl, 7 M Gdm•Cl pH 7.0). 800 μL of solution A is charged into 
a quartz cuvette equipped with a stir bar, to which solution B was added in fractions. Before each 
addition, equal volume of the solution in the cuvette is taken out. A two-minute equilibration time 
was allowed after each addition, and then the ellipticity at 225 nm was recorded. Plotting the 
ellipticity data against Gdm•Cl concentration yielded the denaturation curves, which were fitted 
using the standard baseline extrapolation method (Fig. S3-3) to give the thermodynamic 
parameters listed in Table 3-2 (Cm, m value, and ΔGf). 
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Figure 3-20. Guanidinium chloride denaturation of HP35 variants. (A) Denaturation data of HP35 F6Zp, 
displaying well-defined pre- and post-transition baselines. (B) Plots of folding free energies against 
guanidinium chloride concentration for HP35 variants, linear fit of which yielding m and ΔGf values (Table 
xx in the main text). 
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PART II. Quadrupole interactions in face-face stacked aromatic-fluorinated aromatic pair 
 
I. General methods 
5(6)-Carboxytetramethylrhodamine(TAMRA) and HBTU was purchased from Novabiochem 
(San Diego, CA). 4-Fluoro-7-nitro-2,1,3-benzoxadiazole(NBD-F) was purchased from TCI 
America (Wellesley Hills, MA). Fmoc-L-pentafluorophenylalanine was purchased from Chem-
Impex Int’l Inc (Wood Dale, IL). All other Fmoc-protected amino acids were purchased from 
Advanced Chemtech (Louisville, KY). TMAO (Trimethylamine N-oxide dihydrate) was 
purchased from Sigma Aldrich (St. Louis, MO). Peptide syntheses were carried out on a Tribute 
peptide synthesizer (Protein Technologies, Tucson, AZ). MS data were generated by Boston 
College Mass-Spec facilities. Peptide concentration measurements were performed on a Lambda 
25 UV-Vis spectrometer (PerkinElmer, Waltham, MA). Circular dichroism measurements were 
performed on an AVIV CD spectrometer (Aviv Biomedical Inc. Lakewood, NJ).  
 
II. Peptide synthesis and characterization 
The α2D variants were synthesized through the standard Fmoc/tBu chemistry with the Fmoc-
Gly-Wang resin (Novabiochem) as the solid support. The syntheses were carried out on 0.1 
mmole scale. Five equivalents of the Fmoc-protected natural amino acids were used for the 
coupling reaction. The incorporation of the pentafluorophenylalanine (Z) was accomplished by 
using two equivalents of the Fmoc-protected amino acid and an extended coupling time (1 hour). 
The peptides were cleaved off the resin and deprotected with reagent K (80% TFA, 5% H2O, 2.5% 
EDT, 5% Thioanisole and 7.5% phenol). The crude products were purified by RP-HPLC (Waters 
Prep LC, Jupiter C18 Column), followed by gel filtration (ÄKTA FPLC with Hiload
TM
 
Superdex
TM
 30 prep grade Column). Peptide concentrations were determined by UV-Vis 
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absorption at 280 nm using the extinction coefficient of 5690 M
-1
·cm
-1. The sequences of the α2D 
variants are:  
                          10                                             29 
WT:      GEVEELEKKFKELWKGPRRGEIEELHKKFHELIKG 
F29Z:      GEVEELEKKFKELWKGPRRGEIEELHKKZHELIKG 
F10Z:       GEVEELEKKZKELWKGPRRGEIEELHKKFHELIKG 
F10,29Z:  GEVEELEKKZKELWKGPRRGEIEELHKKZHELIKG 
The NBD labeled WT (WT-NBD) and TAMRA labeled F10,29Z (F10,29Z-TAMRA) were 
synthesized by coupling the fluorophore onto the N-termini of the peptides with a β-alanine as a 
linker. The coupling with NBD-F was carried out by adding three equivalents of NBD-F to the 
peptide on resin in the presence of an excess amount (10 equivalents) of N,N-
diisopropylethylamine (DIPEA). TAMRA coupling followed the standard coupling step for 
Fmoc-protected amino acids: three equivalents of TAMRA were activated by HBTU and ten 
equivalents of N-methylmorpholine (NMM). The coupling reaction for both fluorophores was run 
for 15 h. The cleavage and purification followed the same protocol described above for the 
unlabelled peptides.  
All peptides were characterized by LC-MS to confirm the identity of the peptides (Table 3-4) 
and make sure that the purity is greater than 95%.  
Table 3-4. ESI-MS data of the α2D variants 
 WT F29Z F10Z F10,29Z WT-NBD F10,29Z-TAMRA 
MWcalcd (Da) 4248 4338 4338 4428 4482 4911 
MW[M+] (Da) 4247 4337 4337 4426 4479 4909 
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III. Circular dichroism spectroscopy 
The α2D variants were dissolved in a phosphate buffer (20 mM NaPi, 150 mM NaCl, pH 7.3) 
for circular dichroism spectroscopy. The CD spectra were recorded on an AVIV 202SF CD 
spectrometer equipped with a temperature-controlled cell holder using a quartz cell with 2 mm 
light path length. The data were collected at 2 °C over the wavelength range of 200-260 nm, with 
1 nm step size. The integration time used was 3 seconds. Three wavelength scans were recorded 
and averaged for all protein samples.   
 
IV. The FRET assay for heterodimerization of WT and F10,29Z. 
In the FRET assay WT and F10,29Z were labeled with NBD and TAMRA respectively. The 
heterodimer formation should trigger the fluorescence energy transfer from NBD to TAMRA.  
The concentration of the labeled peptides were determined by measuring the absorbance at 
466nm for WT-NBD (466nm=22,000 cm-1·M-1), and 555 nm for F10, 29Z-TAMRA 
(ε555nm=91,000 cm-1·M-1). The samples of WT-NBD and F10,29Z-TAMRA were prepared with 
a concentration of 50 μM in a phosphate buffer (20 mM NaPi, 150mM NaCl, pH 7.3). The 
mixture was prepared to have the concentration of 50 μM for each component. The fluorescence 
emission spectra were recorded on a fluorescence spectrometer (Horiba Jobin Yvon Fluorolog FL 
3-22) with the excitation at 460 nm. The emission data were collected from 500 nm to 700 nm. 
 
V.Gel filtration experiments. 
The gel filtration experiments were carried out on an ÄKTA FPLC™ system (GE Healthcare, 
Piscataway, NJ) with a HiLoad
TM
 Superdex
TM
 30 prep-scale column.  
The peptides were firstly dissolved in 2 ml running buffer (50 mM Tris, pH 7.3) in a 
concentration range of 250~500 μM, and then injected into the column individually. The flow 
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rate was set to 1 ml/min. The column volume was 120 ml. The retention time of each peptide was 
monitored by the UV absorption at 280 nm (Figure 3-21). The two control peptides used were 
Ribonuclease A (13.7 kDa) and Chicken Villin Headpiece Subdomain (4.5 kDa).  
 
Figure 3-21. Gel filtration analyses of the α2D variants and two protein controls.  
 
VI. 
1
H-NMR and 
19
F-NMR of α2D variants 
All the NMR samples were prepared in a phosphate buffer (20 mM NaPi, pH 5.5, 10% D2O). 
The peptide concentration used for 
1
H-NMR was 400 μM; the mixture has 400 μM for each of the 
components.  For 
19
F-NMR, the sample concentration was 3 mM; the mixture has 3 mM for each 
component. All NMR data were collected at 25 C. The chemical shifts were calibrated against 
the water peak for 
1
H-NMR and CF3COOH for 
19
F-NMR. The 
1
H-NMR experiments were done 
with the Watergate method to suppress the water peak. All data were processed with MestreNova 
software package.  
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VII. Thermal denaturation analysis of the α2D homodimers 
The thermal denaturation experiments were monitored on a CD spectrometer at 222 nm over 
the temperature range of 2-110 °C for F10Z and F10,29Z and 2-98 °C for WT and F29Z. The 
ellipticity data were collected with 2 °C step size, 90 s equilibration time and 30 s data integration. 
Reverse temperature scan yielded the renaturation curve that perfectly overlays with the 
denaturation curve (Figure 3-22A).  In addition, identical CD spectra were observed for the 
renatured sample and the sample before the thermal cycle (Figure 3-22B). These results indicate 
that the 2D (un)folding is completely reversible. 
 
For each protein variant, thermal melting curves were recorded at five different 
concentrations. All melting curves (Figure 3-23) were fitted into a two-state model (J. Am. Chem. 
Soc., 1995, 117, 7559), which yielded the melting temperature (Tm) values. The data are 
summarized in Table 3-5.  
 
Figure 3-22. (A) Thermal denaturation and renaturation curves of (F29Z, F29Z) (50 μM in a phosphate 
buffer with 20 mM NaPi, 150 mM NaCl, pH 7.3). (B) CD wavelength scans of (F29Z, F29Z) before and 
after thermal cycle, demonstrating the complete reversibility of α2D folding (30 μM in a phosphate buffer 
with 20 mM NaPi, 150 mM NaCl, pH 7.3). 
(A) (B) 
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Figure 3-23. Thermal denaturation curves of the α2D variants at varied concentrations. (A): (WT, WT); (B): 
(F29Z, F29Z); C): (F10Z, F10Z); D): (F10,29Z, F10,29Z). 
  
(A) (B) 
(C) (D) 
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Table 3-5. Total monomer concentrations of the α2D homodimers used in thermal denaturation 
experiments and the corresponding Tm values. 
(WT, WT) (F29Z, F29Z) (F10Z, F10Z) (F10,29Z, F10,29Z) 
Ctotal (μM) Tm(C) Ctotal (μM) Tm(C) Ctotal (μM) Tm(C) Ctotal (μM) Tm(C) 
25 29.8 10 59.2 10 67.0 5 72.1 
50 36.5 20 62.5 20 70.6 10 75.7 
100 39.0 30 64.1 30 72.0 15 77.0 
150 42.1 50 65.9 50 74.7 20 78.3 
200 44.3 75 67.1 74 75.5 30 81.1 
 
Thermal stabilities of the NBD labeled WT and TAMRA labeled F10, 29Z were also 
evaluated by thermal denaturation experiments. As expected, there were no major changes caused 
by the fluorophores, when compared to the unlabeled peptides. (Figure 3-24). The melting 
temperature for 50 μM WT-NBD is 41.0 C, only 4.5 C higher than the WT at the same 
concentration. A Tm value of 71.7 C was obtained for 15 μM F10, 29Z-TAMRA, which is 5.3C 
lower than that of the unlabeled F10, 29Z at the same concentration. 
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Figure 3-24. Thermal denaturation profiles of the fluorophore-labeled 2D homodimers (WT, WT) and 
(F10,29Z, F10,29Z) in comparison to the corresponding unlabeled proteins.  
 
VIII. van’t Hoff analysis of 2D dimerization 
van’t Hoff equations are shown below:  
dT
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    Eq. 2                             
Where, Gf is the folding free energy of 2D, Hf is the folding enthalpy, Kf is the 
association equilibrium constant, and T is temperature.    
If we assume the folding enthalpy ΔHf is constant in the temperature range of our 
measurement, eq. 2 can be integrated to give: 
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    Eq. 3 
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Therefore, plots of ln(Kf) against 1/T should yield a linear relationship, with the slope being  -
Hf /R.                       
At the melting temperature of a protein sample with total monomer concentration of Ctotal, 
half of the protein exists as folded dimers, the other half as unfolded monomers. Therefore, the 
unfolded monomer concentration (Cmonomer) should be half of Ctotal, while the folded dimer 
concentration (Cdimer) should be half of the unfolded monomer, i.e.  
Cmonomer=2Cdimer=0.5Ctotal   Eq. 5 
Then the equilibrium constant can be calculated as: 
totalmonomer
er
f
CC
C
K
1
2
dim 
    Eq. 6 
With the Kf values calculated, plots of ln(Kf) against 1/T can be fit into linear relationship (Eq. 
3). The folding enthalpy values (Hf ) can be calculated from the slope of the linear fits (3-13, 
main text and Table 3-6).  
Integration of Eq. 1 gives: 
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  Eq. 7                            
 If we set T1 being at the Tm value of the sample with the protein concentration of Ctotal1, 
Gf1/T1=-Rln(Kf1)=Rln(Ctotal1), then Eq. 7 can be rearranged to: 
)ln(1 12
2
2 total
1
ff CRT)
T
T
(ΔHG Δ
   Eq. 8      
Based on this equation, the folding free energy Gf2 at T2 can be calculated. We calculated 
Gf2 values at 37C, with the results listed in Table 3-6. 
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Standard Error estimation for Hf and Gf  values 
Linear fit of van’t Hoff plots gives the standard error of the slope, from which the standard 
error of Hf can be easily calculated.  
The standard error of Gf, d(Gf), is calculated according to Eq. 8 
)]ln([]1[)( 12
2
2 total
1
ff CRTd)
T
T
(ΔHdGd Δ
 Eq.9 
T2 is set at 37C; T1 is one of the measured Tm values, which normally yield an error of 1 
Kevin. The percentage error d(T1)/T1  is very small (<0.3%), therefore, T1 is considered a 
constant in Eq. 9. Ctotal1 is the pre-fixed protein concentration, hence considered as a constant as 
well. Taken together, Eq. 9 can be rewritten as: 
)1()()( 22
1
ff
T
T
ΔHdGd Δ
     Eq.10 
Therefore, the standard error for Gf values can be estimated from the error values of Hf 
and listed in Table 3-6. 
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Table 3-6. Thermodynamic parameters of the 2D homodimers 
a. calculated by fitting thermal denaturation curves of 20 μM peptide concentration. b calculated from 
the linear fit of the van’t Hoff plots (Eq. 3). c calculated from Hf, according to Eq. 8. 
 
IX. GdmCl denaturation of α2D variants 
The guanidinium chloride (GdmCl) denaturation data of the α2D variants were collected at 2 
C on a circular dichroism spectrometer. TMAO, a well-known stabilizing osmolyte, was 
included to improve the protein stability. Two protein solutions were prepared with the 10 M 
protein concentration for both: solution A is in the native folding buffer (20 mM NaPi, 150 mM 
NaCl, 2M TMAO, pH 7.3) and solution B is in the denaturing buffer (20 mM NaPi, 150 mM 
NaCl, 6 M GdmCl, 2M TMAO pH 7.3). 1800 L of solution A was charged into a quartz 
cuvette equipped with a stir bar, to which solution B was added in fractions. Before each addition, 
equal volume of the solution in the cuvette was taken out. Two minutes equilibration time was 
allowed after each addition, and then the ellipticity at 230 nm was recorded. Plotting the 
ellipticity data against GdmCl concentration yielded the denaturation curves (an example shown 
in Figure 3-25). The α2D variants turned out to be highly sensitive toward GdmCl denaturation; 
Protein Tm
a
 
(C ) 
Hf 
b 
 (kcal/mol) 
Gf 
c
 at 37 C  
(kcal/mol)  
(WT, WT) 28.9 -28.4 ± 2.6 -5.9 ± 0.1 
(F29Z, F29Z) 62.5 -53.7 ± 3.1 -10.9 ± 0.2 
(F10Z, F10Z) 70.6 -57.0 ± 4.2 -11.8 ± 0.4 
(F10,29Z, F10, 29Z) 78.3 -50.1 ± 3.1 -12.6 ± 0.3 
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no pre-transition baseline was observed, even in presence of 2 M TMAO. Therefore, GdmCl 
denaturation data failed to give the thermodynamic parameters of the α2D variants. 
 
Figure 3-25. GdmCl denaturation of WT in a buffer containing 2M TMAO. No pre-transition baseline 
was observed. 
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X. Structural modeling of the stacking Phe pair in 2D 
Structural modeling and analysis of 2D were carried out with Pymol. Careful examination of 
the local structure of the Phe pair led to the conclusion that the edge-face packing is unlikely to 
exist within the hydrophobic core of 2D. Forcing the Phe pair into the edge-face geometry 
introduces steric clashes as shown in structural model below.   
 
Figure 3-26. A structure model of 2D showing that the edge-face packing of the Phe pair introduces 
multiple steric clashes. F29 of the monomer in green are rotated to afford a T-shaped contact with F10 of 
the monomer in slate blue. Severe steric clashes are observed between the Phe pair and between the F29 
side chain and the L25 CO. These relevant substructures are shown as spheres.   
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XI. Energetic analysis of the F-to-Z mutation in 2D 
An F-to-Z mutation in a protein could perturb protein stability by a number of factors in 
addition to the quadrupole interaction that is the focus of this report. Such factors include 
hydrophobicity, steric effects and multipolar interactions involving the C-F bonds, which are 
discussed in great detailer below. It is worth noting that these energy factors are counted into the 
Gother term; they cancel out during the double mutant cycle analysis, thus, do not affect the 
Gquad value estimated in the main text.  
1) The calculated LogP values for toluene and pentafluoro-toluene are 2.52 and 3.31 
respectively. Hence, an F-to-Z mutation could contribute ~ 1kcal/mol to protein stability due to 
the super-hydrophobicity of the Z side chain. (F10,29Z, F10,29Z) harbors four Z residues, the 
hydrophobicity of which presents a major energetic factor for the observed high stability of the 
fluorinated  2D (-6.7 kcal/mol more stable than the WT). 
2) The Z side chain is slightly bigger than the F side chain (130 Å
3
 vs. 103 Å
3
). It remains 
unclear to what scale the steric difference affects protein stability. 
3) We have carefully examined the structure of 2D and identified two potential weak polar 
interactions involving the C-F bonds (Figure 3-27), the energetic scale of which merit further 
investigation. 
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Figure 3-27. Possible weak polar interactions between the C-F bonds and neighboring residues. The 
substructure are colored as follows: C: green for one monomer and slate blue for the other; N: blue; O: red; 
F: orange; H: white.   
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